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ABSTRACT 
 
In response to telomere shortening, oxidative stress, DNA damage or aberrant 
activation of oncogenes, normal somatic cells exit the cell cycle and enter an 
irreversible growth arrest termed senescence. The limited proliferative capacity 
imposed by senescence on cells impedes the accumulation of mutations 
necessary for tumorigenesis and prevents proliferation of cells at risk of 
neoplastic transformation. Opposite to the tumor suppressor function, 
accumulation of senescent cells in adult organisms is thought to contribute to 
aging by depleting the renewal capacity of tissues and stem/progenitor cells, and 
by interfering with tissue homeostasis and functions. The Antagonistic Pleiotropy 
Theory of senescence proposes that senescence is beneficial early in life by 
acting as a tumor suppressor, but harmful late in life by contributing to aging. 
Recent studies have provided evidence strongly supporting the tumor suppressor 
function of senescence, however, direct evidence supporting the role of 
senescence in aging remains largely elusive.   
 In this thesis, I describe studies to test the Antagonistic Pleiotropy Theory 
of senescence in tumorigenesis and aging. The approach that I have taken is to 
alter the senescence response in vivo by changing the expression of a 
senescence regulator in mice. The consequence of altered senescence response 
on tumorigenesis and stem cell self-renewal was investigated. The senescence 
regulator I studied is Smurf2, which has been shown previously to activate 
senescence in culture. I hypothesized that the senescence response will be 
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impaired by Smurf2 deficiency in vivo. Consequently, Smurf2-deficient mice will 
develop tumors at an increased frequency, but also gain enhanced self-renewal 
capacity of stem/progenitor cells with age. 
I generated a Smurf2-deficient mouse model, and found that Smurf2 
deficiency attenuated p16 expression and impaired the senescence response in 
primary cells and tissues. Smurf2-deficient mice exhibited an increased 
susceptibility to spontaneous tumorigenesis, indicating that Smurf2 is a tumor 
suppressor. At the premalignant stage of tumorigenesis, a defective senescence 
response was documented in the Smurf2-deficient mice, providing a mechanistic 
link between impaired senescence response and increased tumorigenesis. The 
majority of tumors developed in Smurf2-deficent mice were B-cell lymphomas 
with an origin in germinal centers of the spleen and a phenotype resembling 
human diffuse large B-cell lymphoma (DLBCL). I discovered that Smurf2 
mediated ubiquitination of YY1, a master regulator of germinal centers. 
Stabilization of YY1 in the absence of Smurf2 was responsible for increased cell 
proliferation and drove lymphomagenesis in Smurf2-deficient mice. Consistently, 
a significant decrease of Smurf2 expression was observed in human primary 
DLBCL samples, and more importantly, a low level of Smurf2 expression in 
DLBCL correlated with poor survival prognosis. Moreover, I found that 
hematopoietic stem cells (HSCs) in Smurf2-deficient mice had enhanced function 
compared to wild-type controls. This enhanced stem cell function was associated 
with increased cell proliferation and decreased p16 expression, suggesting that 
defective senescence response in Smurf2-deficient mice leads to increased self-
ix
renewal capacity of HSCs. My study, for the first time, offers direct genetic 
evidence of an important tumor suppressor function for Smurf2 as well as its 
function in contributing to stem cell aging. Collectively, these findings provide 
strong evidence supporting the Antagonistic Pleiotropy Theory of senescence in 
tumorigenesis and aging. 
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CHAPTER I 
 INTRODUCTION 
2
Since the focus of my thesis is on studying the antagonistic roles played by 
senescence in regulating varied processes such as tumorigenesis and aging, in 
the first part of this chapter I will present a general overview of senescence 
including factors that activate the senescence response, and the pathways 
regulating senescence. This will be followed by a review of what is currently 
known about the function of senescence as a tumor suppressor and in aging, 
with specific emphasis on the functional manifestations and factors regulating 
HSC aging.  
 
Cellular Senescence 
 
Cellular Senescence is defined as a state of irreversible growth arrest from which 
cells cannot be stimulated to divide. It was described by Hayflick and Moorhead 
in normal human fibroblasts in a seminal study which for the first time defined 
cultured cells as having a finite replicative life span [1]. Senescent cells remain 
arrested in the G1-G0 phase of the cell cycle and do not respond to growth 
factors [2,3]. They are also apoptosis resistant [4,5], and associated with 
changes in morphology including assuming a flat, enlarged shape referred to as 
‘fried egg’ appearance [6]. Senescent cells are also characterized by the 
expression of Senescence-associated β-Galactosidase (SA-β-Gal) activity [7], 
and unique gene expression signatures [8-12].  
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Triggers of Senescence: 
Telomere dependent senescence- 
Telomeres consist of many kilobases of TTAGGG repeats found at the very ends 
of chromosomes. The telomeric TTAGGG repeats shorten with each cell division 
due to the end replication problem [13-16]. Telomerase, the enzyme responsible 
for adding telomere repeats to the ends of chromosomes [17] is not present in 
somatic cells, and its absence leads to progressive telomere shortening [18,19], 
which is thought to be the primary cause of replicative senescence [20,21]. 
Further, the adventitious expression of Telomerase Reverse Transcriptase 
(TERT) prevents telomere shortening and inhibits the induction of senescence in 
somatic cells [22-24]. Complementary to this finding, the attenuation of 
telomerase in immortal cells leads to induction of replicative senescence [25,26]. 
Telomeres which have reached the critical short length lose the protection of the 
capping proteins that are usually present at their ends [16]. Further, these 
uncapped telomeres are recognized as sites of DNA damage and recruit DNA 
damage response proteins such as 53BP1, γH2AX, MDC1 and MRE11 [27-29].  
 
Telomere independent senescence- 
Other stressors can also induce senescence. These include oncogene activation 
[30-32], DNA damage [33,34], oxidative stress [35-37], and inadequate culture 
conditions [37-39], and damage to chromatin structure [40-42]. These are 
referred to as stress-induced premature senescence. These types of senescence 
are independent of telomere length and cell divisions [43-45].  
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Stress-induced premature senescence and telomere dependent senescence 
result in similar final outcomes and share common changes in expression of cell 
cycle regulators and other morphological properties [31,35,33,34].  
In addition to the cell cycle regulatory genes, the expression of DNA 
damage checkpoint genes, inflammation and stress-associated genes, genes 
encoding extracellular matrix proteins and extracellular matrix-degrading 
enzymes, and cytoskeletal genes and metabolic genes is generally altered during 
replicative and premature senescence. Recent studies suggest that DNA 
damage could be a common cause for different forms of senescence induced by 
various stimuli [9,10,12]. Senescence is now considered as a general stress 
response in normal cells to various types of cellular damage [46]. 
 
Molecular pathways regulating senescence: 
All the various senescence-inducing stimuli trigger the senescence response 
through multiple genetic pathways. These pathways finally converge upon the 
p53 and Rb pathways and inactivation of both pathways is essential to abolish 
the senescence response.  
 
The p53 pathway- 
In senescent cells, p53 is phosphorylated and its transactivation activity is 
elevated, although its mRNA and protein levels are largely unchanged [29,47-
50]. DNA damage response elicited by telomere dysfunction leads to activation of 
ATM/ATR and Chk1/Chk2, which in turn phosphorylate and stabilize p53 
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[27,29,28,51]. In addition, p53 is activated and plays an important role in stress-
induced premature senescence [30,34,52,53]. This p53 activation is mediated by 
p14ARF  (or p19ARF in mouse) encoded by the INK4a/Arf locus. ARF stabilizes 
p53 by sequestering Mdm2, an E3 ubiquitin ligase targeting p53 for degradation 
[54]. The ARF-p53 axis plays an important role during senescence in mouse 
cells. Inactivation of p53 or ARF in mouse embryo fibroblasts (MEFs) is sufficient 
to prevent senescence [55-57]. One of the p53 targets is p21 (CIP1/WAF1), 
whose increased expression transactivated by p53 is responsible for cell cycle 
arrest [58]. The expression of p21 is upregulated during replicative senescence 
[59-61]. This p21 up-regulation is dependent on signal(s) initiated by telomere 
shortening, as expression of TERT blocks this upregulation [62-64]. 
Overexpression of p21 is able to induce a senescence-like growth arrest in some 
cells [65,66], while deletion of p21 can postpone senescent arrest [67,68]. 
Collectively, these studies suggest that p53 regulates senescence at least in part 
by inducing p21.  
 
The p16-Rb pathway- 
In parallel to p21, p16INK4a  (p16) is another cyclin dependent kinase inhibitor 
that leads to pRb hypophosphorylation [58]. The expression of p16 is increased 
during replicative senescence [69-71], but whether increased p16 expression is 
regulated by telomere shortening is controversial. As telomere shortening is the 
major cause of replicative senescence in human fibroblasts [24], and inactivation 
of both the p53 and pRb pathways is required to prevent replicative senescence 
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[72], it is reasonable to expect that dysfunctional telomeres may signal into p16-
pRb axis. There is indeed an example showing that telomere dysfunction induces 
p16 expression [73]. However, the dynamics of p16 and p21 elevation in 
senescent cells are different. The increased expression of p16 occurs after 
senescence has already been established in culture [69,70,74], in contrast to the 
rapid increase of p21 expression in cells approaching replicative senescence 
[62]. Within a senescent population of human cells, some cells express p16, 
while others express p21 [29,75,74]. DNA damage foci at telomeres are found 
only in cells expressing p21, but not in p16 positive cells [29], suggesting that 
p16 elevation is independent of telomere shortening. Consistent with this notion, 
p16 induction during senescence, unlike p21, is not prevented by ectopic 
expression of TERT [76]. 
The expression of p16 is readily increased during premature senescence 
induced by a variety of stressors [30,32,33,38]. It is not entirely clear how p16 
expression is regulated by various senescence signals [77]. Under certain 
circumstances, p16 is coordinately regulated with Arf, which is also encoded by 
the INK4a/Arf locus. For example, polycomb complex proteins have been shown 
to repress the INK4a/Arf locus [74,78,79]. Decreased expression of polycomb 
complex proteins relieves the repression of the INK4a/Arf locus and is 
responsible, at least in part, for the elevation of p16 and Arf in senescent cells 
[74,79].  
The expression of p16 varies significantly among different human cell lines 
[74], and this variable expression seems to hold the key as to whether p53 and 
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pRb function in a linear or in a parallel manner to regulate senescence. In cells 
with low or no p16 expression, p53 and pRb may function in a linear pathway, 
whereas p53 and pRb work in parallel in cells with significant p16 expression. In 
mouse embryo fibroblasts (MEFs), inactivation of p53 or ARF, but not p16, is 
sufficient to prevent senescence [56,57,80], indicating that p53-Arf axis is the 
major regulator of senescence pathway in mouse cells. Human mammary 
epithelial cells quickly encounter a state of growth arrest that is not associated 
with telomere shortening but mediated by p16 up-regulation [81]. A subset of 
cells with p16 inactivation emerge from the arrested population and continue to 
divide until reaching a second growth arrest that is associated with telomere 
shortening [81]. Depending on cell types, culture conditions, and the extent of 
stress, inactivation of either p53-p21-pRb or p16-pRb pathway individually, or 
both pathways together, is required to prevent senescence. 
 While senescence was identified as a cell culture phenomenon, its 
functional significance has been recognized in vivo. Senescence is postulated to 
function as a tumor suppressor mechanism by preventing the accumulation of 
mutations necessary for neoplastic transformation. The next portion of this 
Chapter will review what is known about the function of senescence as a tumor 
suppression mechanism.  
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Senescence as a barrier to tumorigenesis: 
Tumorigenesis is a multistep process, in which a normal cell acquires mutations 
in a number of cancer-causing genes [82]. By restricting cell proliferation and 
thereby impeding the accumulation of mutations, senescence acts as an 
important tumor suppression mechanism. Furthermore, senescence induced by 
aberrant activation of oncogenes, oxidative stress, or DNA damage prevents 
cells at risk of malignant transformation from proliferating [44,83]. Senescence 
represents a physiologic response that cells must overcome in order to divide 
indefinitely and develop into tumors. Consistent with the notion that senescence 
is a tumor suppression mechanism, well-established tumor suppressors, 
including p53, pRb, p16, Arf, and p21, are regulators of senescence [77,83].  
In contrast to normal somatic cells, cells derived from tumors divide 
indefinitely in culture. The ability to escape senescence (i.e., immortality) is a 
necessary step for cells to become transformed and one of the hallmarks of 
cancer cells [84]. 80% to 90% of human cancer cells acquire unlimited 
proliferative potential through reactivation of telomerase [18] while the rest 
maintain telomere length by a recombination-mediated process termed 
alternative lengthening of telomeres [85]. These observations in human cancer 
strongly suggest a connection between the telomere checkpoint and tumor 
suppression. Supporting this connection, inhibition of telomerase activity in 
cancer cells limits their growth by triggering telomere shortening and cell death 
[25,26]. Conversely, ectopic expression of telomerase in normal human cells 
leads to immortalization and enhances the ability of these cells to be 
9
neoplastically transformed [23,24]. Furthermore, transgenic mice overexpressing 
TERT show increased propensity to tumorigenesis [86,87]. 
Genetic studies in mice deficient in telomerase provide further support for 
telomere shortening as a tumor suppression mechanism. Mice deficient in the 
telomerase RNA component (mTERC−/−) gradually lose telomeres over several 
generations [88] and tumorigenesis is significantly reduced in late generations of 
mTERC−/−  mice with telomere attrition [89-93]. Decreased tumorigenesis is also 
observed in late generations of mice with a null mutation in telomere catalytic 
subunit (mTERT−/−), and p53 mutation enables tumor progression in these mice 
[94]. More importantly, two studies provide evidence that senescence induced by 
telomere shortening is responsible for tumor suppression [95,96]. When 
apoptosis is blocked by the expression of Bcl-2 or a specific p53 mutant (R172P), 
shortened telomeres reduce tumorigenesis in mTERC−/−  mice. Suppression of 
tumor development requires p53-dependent activation of senescence [96,95], 
demonstrating that senescence induced by telomere shortening is an effective 
tumor suppression mechanism in vivo.  
The discovery that oncogenic Ras protein can induce a senescent arrest 
after causing an initial hyperproliferation in normal cells suggests that induction of 
senescence is an intrinsic cellular response that prevents cells at risk from 
proliferating [30]. In mouse tumor models with oncogenic Ras, senescent cells 
are found in premalignant lesions in lung [97], spleen [98], breast [99] and 
pancreas [100]. The observation of senescent cells has been extended to many 
premalignant lesions or benign tissues induced by activation of different 
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oncogene or inactivation of tumor suppressor in mouse [101-104] and human 
[101,105,106]. Importantly, senescent cells are absent in malignant tumors [97-
99,103,106] suggesting that oncogene induced senescence is a powerful tumor 
suppression mechanism by restricting proliferation of cells with oncogenic 
mutations and this senescence block must be evaded for malignancy to 
progress. Consistently, deletion of senescence regulators such as p53, Arf, p16, 
or PRAK abrogates senescence and causes progression of tumors to the 
malignant stage [98,101,103,104]. These observations point to a causal link 
between loss of senescence and malignant transformation. 
Since the discovery of senescence in cultured cells, it is recognized that 
cellular senescence and organismal aging may be closely related because of 
their shared ability to limit lifespan [20]. It is hypothesized that constant tissue 
regeneration results in accumulation of senescent cells in somatic tissues, which 
limits tissue renewal, perturbs normal tissue homeostasis and ultimately leads to 
aging [107,83]. In the next portion of this chapter, I will present an overview of 
what is known about the role of senescence in aging.  
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Senescence and Aging: 
Cells with characteristics of senescence have been reported to increase with 
advancing age in mice, primates and humans [7,108-110]. In addition, 
accumulation of senescent cells is linked with age-associated pathological 
conditions, such as osteoarthritis [111], atherosclerosis [112,113], and liver 
cirrhosis [114]. The initial support for the senescence theory of aging comes from 
the observation of an inverse correlation between the in vitro lifespan of cells and 
the age of donors from which they are derived [115-117], although this 
correlation has been disputed [118]. Subsequent support comes from studies of 
cells derived from progeroid patients, such as Werner syndrome, which achieve 
fewer cell divisions before entering senescence than cells derived from normal 
individuals of same age [119]. 
Recent studies suggest that the telomere checkpoint plays an important 
role in the aging process. It is evident that telomere shortening occurs in aged 
human tissues [120-125], at sites of age-related pathological conditions 
[126,114], or associated with stress and obesity [127,128]. Although it remains to 
be demonstrated whether telomere shortening leads to the accumulation of 
senescent cells in vivo, and more importantly makes a substantial contribution to 
aging, studies of human premature aging syndromes support a link between 
telomere attrition and aging. Patients of dyskeratosis congenita and aplastic 
anemia have mutations in telomerase RNA or catalytic subunit [129-131], and 
are characterized by accelerated telomere shortening [132,129]. Further 
evidence for a role of telomere attrition in aging comes from genetic studies of 
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mice deficient in telomerase. While mice with a null mutation in telomerase RNA 
(mTERC−/−) are apparently normal in early generations, these mice in later 
generations gradually lose telomeres [88] and show accelerated aging 
phenotypes [133,134]. Similarly, premature aging phenotypes are observed in 
mTERC−/− mice on a CAST/EiJ background, which have shorter and more 
homogenous telomere length than C576BL/6 strain. Even with the presence of 
telomerase, shortened telomeres in mTERC+/−  mice on CAST/EiJ background 
are associated with premature aging [135]. A recent study shows that telomerase 
reactivation can reverse much of the premature aging phenotypes in telomerase-
deficient mice [136], indicating that telomere attrition plays a critical role in aging. 
Furthermore, mutations in WRN or BLM in the telomere dysfunctional 
background in the mouse cause premature aging phenotypes that are 
characteristics of Werner or Bloom syndrome in humans Such premature aging 
phenotypes are absent in mice with WRN or BLM mutation but with long 
telomeres [137,138]. These studies clearly establish a link between telomere 
attrition and aging. Whether this link is mediated through senescence triggered 
by telomere shortening is currently unknown.  
Apart from the proliferating cell compartments, the self-renewing stem cell 
compartments in the body have also been postulated to undergo senescence 
with age. While the exact role of senescence in stem cell aging is unknown, the 
functional consequences of stem cell aging have been studied in a number of 
stem cell compartments. In Chapter 4 of this Thesis I examined the role of 
Smurf2-deficiency, and consequently, of senescence, in the HSC compartment 
13
of young and aging mice.  Therefore, the next portion of this chapter will focus on 
the consequences and mechanisms of stem cells in aging with an overview of 
what is known about senescence in stem cell compartments.  
 
Stem cells and Aging: 
Stem cells are present in most adult mammalian tissues and they are responsible 
for maintaining normal tissue homeostasis and regeneration in response to 
damage [139,140]. As aging is accompanied by a reduced homeostatic and 
regenerative capacity in all organs, it is a reflection of the declining stem cell 
activity in the organs with age [141-143]. Stem cell aging is somewhat 
distinguishable from aging in younger, more proliferative cells. The functional 
manifestations of stem cell aging include the failure to self-renew, decreased 
extrinsic signals as well as signal responsiveness and aberrant progenitor 
differentiation. Each of these processes is reviewed in detail below with particular 
emphasis on the impact of aging in the HSC compartment, as that is the stem 
cell compartment I chose to examine in order to study the functional 
consequences of delayed senescence in aging.  
 
Failure to self-renew- 
The inability of stem cells to self-renew with age is associated with a reduction in 
stem cell number with age. This is especially seen in stem cell compartments 
such as the brain and skin. The stem cell number that efficiently contributes to 
generation of neurons and melanocytes decreases with age [144,145]. This 
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decreased formation of murine Neural Stem cells (NSCs) has been associated 
with a progressive Parkinsonian disease [91] as well as reduced olfactory 
discrimination with aging [146]. 
Similarly, hair graying has been linked to decreased melanocyte stem-cell 
maintenance, likely associated with melanoblast senescence [147]. These stem 
cell compartments exhibit formation of progeny that don’t maintain the stem cell 
pool as they age. In flies, oogenesis and spermatogenesis abate gradually with 
age, and this coincides with a significant drop in the number of germinal stem 
cells (GSC) as well as reduced stem cell self-renewal capacity of the GSCs that 
are remaining [148-150]. 
Aged hematopoietic stem cells (HSCs) are known to be impaired in 
supporting hematopoiesis. In mice, while there is a strain-dependent increase in 
hematopoietic stem cell (HSC) number with age [151-154], it is associated with a 
dose-dependent decrease in self-renewal capacity in serial transplantation 
experiments in vivo [155,156]. This decline in HSC function increases with the 
number of stem cell transplantations [157-161]. HSCs from aged mice also 
exhibit a decrease in competitive repopulating ability compared with younger 
counterparts [162,151,153].  
 
Decreased extrinsic signals as well as signal responsiveness- 
The defects in tissue homeostasis or regenerative potential with age may be 
because of decreased intrinsic responsiveness of the stem cells, or attenuated 
signals from the external environment to the stem cells. For example, muscle 
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stem cells (MuSCs) undergo changes in their niche, which leads them to affect a 
low response to extrinsic stimuli with age, and this leads to the decreased 
regenerative response [163,164]. This is associated with changes in their niche, 
which is the myofibre adjacent to the MuSc [165]. Older myofibres express lower 
levels of the Notch ligand Delta-like 1 that is essential for stem cell activation 
[166,167]. In older flies, systemic factors such as the Drosophila insulin-like 
peptides (dILPs) also influence GSC proliferation and maintenance. Reduced IIS 
signaling is seen in the ovary of older females [168-170].  
HSCs in the bone marrow are also located in close proximity to the non-
hematopoietic cellular elements, and it is hypothesized that the bone marrow 
niche plays an important role in HSC regulation [171]. The niche evolves and 
undergoes changes with age and therefore influences HSC function in aging. As 
the animal ages, DNA damage accumulates within the HSCs and they attempt to 
cope with this accumulation by activating tumor suppressor pathways. Mice 
deficient in proteins that are involved in essential DNA repair pathways such as 
nucleotide excision repair, telomere maintenance and non-homologous end-
joining exhibit alterations in number as well as attenuation in HSC function. 
These phenotypes recapitulate some phenotypes of normal aging [172]. Wild-
type HSCs show an accumulation of γ-H2AX foci, a marker of DNA damage, with 
age [172]. Further, recent studies have shown such accumulation of DNA 
damage in human hematopoietic stem and progenitor cells [173]. 
The role of the bone marrow microenvironment on HSC aging has also 
been studied. When bones from young mice were subcutaneously implanted into 
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older mice, they exhibited decreased repopulating ability [174]. Also, stromal 
cells from older mice display attenuated capacity to support primitive 
hematopoietic bone marrow cells in culture [175]. When time-lapse 2-photon 
microscopy was performed to quantify the dynamics of young and old 
hematopoietic cells inside the marrow of long bones of mice in vivo, it was found 
that the aged early hematopoietic progenitor cells (eHPCs) displayed increased 
cell protrusion movement in vivo and localized more distantly to the endosteum 
compared with young eHPCs [176]. This further correlated with reduced 
adhesion to stroma cells as well as reduced cell polarity upon adhesion of aged 
eHPCs [176]. This result suggests that the changes in eHPC dynamics and cell 
polarity with age lead to an altered niche biology, which plays an important role in 
HSC aging. HSCs from older mice are also known to exhibit homing deficiencies 
when transplanted into older recipients [177], suggesting that the 
microenvironment is an important determinant of stem cell homing with age.  
 
Aberrant progenitor differentiation- 
Stem cells give rise to a number of progenitor cells, which then form effector cells 
that function to maintain tissue homeostasis and function. As the organism ages, 
the stem cells may not efficiently function to produce the right type and number of 
progenitor cells. This might result in skewing of the progenitor cell type to one 
particular fate, and further aberrant differentiation to abnormal fates.  
For example, older MuSCs tend to deviate from the muscle lineage and 
produce fibrogenic cells. This leads to impaired regeneration and fibrosis. This 
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has been shown to be due to over activity of the Wnt pathway with age [164]. 
MuSCs treated with Wnt agonists or aged serum lead to the deviation toward the 
fibrogenic lineage [164].  
The decline in hematopoietic competence with age impacts all the blood 
cell lineages. Thymic involution with age leads to reduced T-cell production and 
function as well as a clonal expansion of memory T-cells [178,179]. B-cell 
function also declines with age, leading to less efficient antibody production, and 
there is a similar increase in the memory B-cell population [180-182]. However, 
there is a skewing towards the myeloid lineages with age, which results in the 
sustenance of a pro-inflammatory environment termed ‘inflammaging’ [180]. The 
adaptive and humoral immune responses are thus both affected, and this, in 
combination with the reduced integrity of epithelial barriers, leads to activation of 
the innate immune responses in response to pathogenic challenge. This results 
in the emergence of a chronic inflammatory state (inflammaging) that is 
associated with several age-related diseases [180,183].  
HSCs from aging mice display a skewing toward the myeloid lineage. Mice 
display changes in lineage potential with age, with a decrease in lymphoid output 
while myeloid potential is maintained [151]. This is associated with a decreased 
immune response and increased incidence of myeloid leukemias in older 
populations. Studies in mice have demonstrated that there exist heterogeneous 
HSC populations within the bone marrow that exhibit different predilections to 
give rise to different types of progenitor cell populations. They can be either 
lymphoid-biased, or myeloid-biased or balanced. Single cell transplantations of 
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purified stem cell populations have demonstrated that the clonal contribution to 
different blood cell lineages varies significantly and can be maintained in serial 
passage [184,185]. 
Further, gene expression profiling of long term HSCs from young and old 
mice has shown that genes required for myeloid specification are upregulated, 
but genes mediating lymphoid specification are down regulated in older mice 
[151]. The cause behind the gene expression changes is currently unclear. 
However, studies have shown that entire regions of chromosomes that are 
silenced in young HSCs, are activated in the old HSCs. The converse is also 
true, that is, regions of chromosomes active in young HSCs are inactive in the 
old HSCs [162]. Genes regulating chromatin remodeling were among those that 
changed their expression differentially between young and old HSCs, suggesting 
that epigenetic alterations may be partially responsible for the wide spread 
changes in gene expression with age.  
Intestinal stem cells (ISCs) from the Drosophila midgut are known to 
proliferate more with age. This leads to the accumulation of misdifferentiated 
daughter cells that express markers of both ISCs and terminally differentiated 
cells [186-188]. Defective misdifferentiation in the midgut leads to deterioration of 
the midgut epithelium in older flies [187]. Such changes in midgut epithelium are 
also observed when the gut is exposed to oxidative stress, tissue damaging 
agents, or bacterial infections of the gut which lead to ISC proliferation and 
misdifferentiation [186,187,189-191]. Chronic exposure to environmental agents 
might also be involved in ISC aging in flies.  
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While the functional consequences of stem cell aging are well known, the role of 
senescence and its contribution to stem cell aging is less clear. There are some 
examples of senescence being an important determinant of stem cell aging. The 
next portion of this chapter will focus on what is currently known about 
senescence in various stem cell compartments.  
 
Senescence in stem cells:  
Thus far, the role of senescence in the changes in stem cell functionality with age 
is debatable. The pathways that regulate senescence are known to be 
upregulated in some stem cell compartments with age, but this does not 
establish a causal link between senescence and aging, but merely provides an 
association between the two. The expression of senescence markers, such as 
senescence-associated B-galactosidase, HP-1 (heterochromatin protein-1) foci, 
and p16INK4a markedly increases with age in many tissues in several 
mammalian species [171]. Studies of self-renewal in HSCs, NSCs and pancreatic 
islet cells from p16INK4a-deficient and p16INK4a-overexpressing mice have 
suggested that increasing levels of p16INK4a are not only associated with aging, 
but partly contribute to the age-induced replicative failure of these tissues [192-
194]. In all three compartments, p16INK4a deficiency attenuated the age-induced 
decline in proliferation and function. Likewise, overexpression of p16INK4a 
attenuated HSC function and islet proliferation in an age-dependent manner. The 
effects of p16INK4a loss were consistent across these distinct stem cell 
compartments, suggesting that p16INK4a can promote aging in tissues, however, 
20
the loss of p16INK4a did not completely abrogate the effects of aging in any of the 
organs studied, suggesting that p16INK4a-independent aging also occurs in each 
of these compartments.  
Other mouse models have also provided evidence to support the role of 
senescence in stem cell aging. The Klotho knockout mouse exhibits a progeroid 
syndrome that is accompanied by elevated Wnt signaling that potentially causes 
stem cell senescence in the skin and gut [195,196]. The role of Wnt signaling in 
stem cell aging has also been demonstrated in the hair follicle stem cells. Normal 
cycling of hair follicle stem cells is regulated by the induction of Wnt proteins in 
the niche, and the return of the cells to quiescence is accompanied by a 
decrease in Wnt activity [197,198]. Transgenic mouse models that constitutively 
activate the Wnt pathway display persistent proliferation of hair follicle stem cells 
followed by signs of premature senescence and disappearance of stem cells that 
correlate with precocious hair loss [196,199]. While this is not a direct 
demonstration, it suggests that hair follicle stem cells may undergo senescence 
during normal aging.  
 Senescence is known to be associated with a critical reduction in 
telomere length and as I have reviewed earlier in this chapter, it is associated 
with aging for this reason. Telomere biology also plays a role in stem cell aging 
and I will now describe briefly what is currently known about the role of telomere 
length in regulating stem cell compartments, specifically the HSC compartment.  
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Telomere Biology in HSC aging: 
Maintenance of telomere length in HSCs is essential, as the blood cells need to 
be continuously replenished during the lifespan of a species. The rate of 
telomere attrition in peripheral blood mononuclear cells (PBMCs) during the first 
3 years of life is more than 4-fold higher than in adults during a 3-year period 
[200]. This high rate of telomere attrition early in life is a reflection of the rapid 
expansion of the HSCs early in life, which is followed by a replicative decline as 
adulthood progresses [201]. Longer telomeres have been found in hematopoietic 
progenitor cells (CD34+) than in mature cells (CD4+, CD8+ cells and 
granulocytes), providing support to the replicative senescence theory in HSCs 
[202,203].  
Telomere biology has been shown to play an important role in bone 
marrow related disorders. Dyskeratosis Congenita (DC), a disease that is caused 
by mutations in the dyskerin (DKC1) gene [204] and results in abnormally short 
telomeres [205] is associated with high risk of Bone Marrow Failure (BMF), 
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). By the 
age of 30, 80-90% of patients develop aplastic anemia and die due to this [206]. 
Further patients with DC are known to have extremely short telomeres compared 
to normal counterparts [207]. Telomere length is also known to be shorter in 
other bone marrow failure disorders such as Fanconi Anemia, Diamond-Blackfan 
syndrome, Shwachman-Diamond Syndrome and Paroxysmal Nocturnal 
Hemoglobinuria [208]. The shorter telomeres in these diseases could be partially 
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attributed to the genetic defect in DNA damage repair pathways, particularly in 
Fanconi Anemia and Shwachman-Diamond Syndrome [209].  
Further evidence for a role of telomere attrition in aging comes from 
genetic studies of mice deficient in telomerase. While mice with a null mutation in 
telomerase RNA (mTERC−/− ) are apparently normal in early generations, these 
mice in later generations gradually lose telomeres [88] and show accelerated 
aging phenotypes [133,134]. Premature aging phenotypes in late generation 
mTERC−/− mice are associated with reduced renewal capacity in highly 
regenerative tissues such as skin, intestine, bone marrow and reproductive 
organs [133-136], suggesting that stem cells may be affected by telomere 
shortening. The self-renewal ability of stem cells is known to decline with 
advancing age, eventually leading to the accumulation of unrepaired, damaged 
tissues in old organisms [107,210]. By limiting cell proliferation, senescence in 
stem cells is hypothesized to contribute to aging by reducing the renewal 
capacity of these cells [20,107,83]. 
Taken together, these two functions of senescence, tumor suppression 
and aging have diametrically opposite effects on the lifespan of a species. While 
tumor suppression is beneficial, aging is detrimental to survival. While tumor 
suppression is beneficial, aging is detrimental to survival. A recent study has 
shown that the accumulation of senescent cells in cutaneous wounds enhances 
the healing process, thus making it beneficial in wound repair [211]. In light of 
another study showing that the accumulation of senescent hepatic stellate cells 
in liver injury limits fibrosis [212], this suggests that senescence may act as a 
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general wound healing response to limit injury and control fibrosis. This role of 
senescence as a double-edged sword has led it to be dubbed an Antagonistic 
Pleiotropic trait. The Antagonistic Pleiotropy Theory is an evolutionary theory of 
aging. Evolutionary theories of aging argue that aging results from a decline in 
the force of natural selection. Darwin’s theory suggests that evolution occurred 
primarily to maximize reproductive fitness in an individual. This implies that 
longevity as a trait would only be selected for if it extended reproductive fitness, 
which it does not. Several evolutionary theories seek to address this problem, 
and they base their predictions on Peter Medawar’s key observation made in 
1952 that beyond a particular age the evolutionary benefit of a longer life span in 
mammals is negligible [213]. He suggested that the force of natural selection 
declines as the organism reaches an age beyond which it cannot reproduce 
efficiently. These evolutionary theories are all in their infancy, and none of them 
has been conclusively validated. One of the offshoots of Medawar’s hypothesis is 
the Antagonistic Pleiotropy Theory that states that cellular and organismal aging 
are caused by genes that have opposing effects on the health of an organism at 
different points in the lifespan of an individual. I have based my thesis work on 
addressing the role of senescence in fulfilling the criteria posed by this theory. 
Therefore the next portion of this Chapter will focus on the Antagonistic 
Pleiotropy Theory and some examples of traits that fit this theory.  
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The Antagonistic Pleiotropy Theory 
 
The Antagonistic Pleiotropy Theory of aging was proposed by George Williams in 
1957 [214] and proposes that cellular damage and organismal aging are caused 
by pleiotropic genes. Pleiotropic genes are genes that have multiple phenotypic 
effects. 
According to this hypothesis, a gene that functions to have beneficial 
effects early in life can have detrimental effects as the organism ages. Williams’ 
original example referred to alleles at loci involved in the calcification of bones. 
Genes that promote efficient calcification would be selected for during early life to 
promote reproductive fitness. The same genes would cause deleterious 
calcification in arteries later in life leading to atherosclerosis. Natural selection 
acts the strongest on traits that manifest during an organism’s peak reproductive 
value, which usually corresponds to the beginning of sexual maturity. This 
benefits the organism by leading to an overall increase in fitness during the 
reproductive period. In contrast, natural selection is the weakest on traits 
manifested after the majority of an organism’s reproduction is complete, and 
impairment to an organism during this time reduce overall fitness less than those 
manifested at earlier ages. Antagonistically pleiotropic alleles are those that 
provide a net increase in reproductive fitness during young age while detrimental 
phenotypes regulated by them are not expressed until post- reproduction [215]. 
The Antagonistic Pleiotropy Theory has been tested mainly in Drosophila 
by using artificial selection experiments [216,217]. Young adult flies were mated 
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with each other and their progeny collected [218,219]. Similarly, progeny derived 
from older adults that were mated were also collected. The older adults tend to 
die more frequently before their offspring were collected, therefore leading to 
stronger selection for longevity in these lines [219-223]. This is demonstrated by 
an increase in the lifespan of the progeny derived from the older matings 
compared the younger lines. Conversely, the flies derived from the younger lines 
demonstrate a reproductive advantage, demonstrating increased fecundity 
compared to the older lines [218,220,222,223]. It was further demonstrated that 
the increased fecundity was responsible for the reduced lifespan in the younger 
lines by experiments in which the reproductive function was abrogated by X-rays 
or genetic means of sterilization. The flies that could not reproduce exhibited 
increased life span showing that the aging was a direct consequence of 
increased fecundity and did not occur because of other effects of aging. There is 
a considerable time lag between the high fecundity associated with early age of 
the young lines and the increase in mortality that it led to, further supporting the 
Antagonistic Pleiotropy Theory.  
Some of the seminal work supporting the Antagonistic Pleiotropy Theory 
has come from studies in the nematode C.elegans. Genes that encode 
components of the insulin signaling pathway when mutated, have been shown to 
give rise to worms with astonishing differences in lifespan compared with wild-
type [224,225]. Worms that are mutant for the gene dauer formation constitutive-
2 (DAF-2), a receptor that responds to insulin-like ligands, display 6.4-fold 
increase in maximum lifespan [226]. Further, reduced insulin signaling in 
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C.elegans also leads to increased dauer formation [227]. In C.elegans aging is 
accelerated by insulin/IGF signaling, which is hypothesized to function by acting 
on the neuroendocrine system [228] in response to food levels. The Antagonistic 
Pleiotropy Theory predicts that the accelerated aging is the trade-off for the 
increased fecundity caused by insulin signaling early in life. As a proof of 
principle, caloric restriction, which decreases insulin signaling is known to extend 
lifespan and reduce fecundity in C.elegans [229]. The Drosophila equivalent of 
DAF-2, is called Inr, and when its function is decreased, mean lifespan of the 
flies increases by 85% [230]. Mouse models deficient in IGF-1 show dwarfism 
and also exhibit a mean increase in lifespan that is associated with reduced 
fecundity [231]. Thus, the insulin signaling pathway is one example of an 
antagonistic pleiotropic trait in species ranging from nematodes to mammals.  
One gene that has been postulated to function as an antagonistic 
pleiotropic trait in mammals is p53. p53 is known to function as a tumor 
suppressor gene by interrupting aberrant cell proliferation. The effect of p53 on 
cell proliferation can be detrimental if it influences the proliferation of normal cells 
such as stem cells that are necessary for self-renewal with aging. The role of p53 
in cancer was initially demonstrated in families with Li-Fraumeni Syndrome, an 
autosomal dominant disorder in which genetic analyses revealed that mutations 
in p53 co-segregated with the disease phenotype [232]. p53 heterozygous mice 
(p53+/-) that lack a single allele of p53 exhibit significantly increased risk of 
cancer [233]. Finally, mice with an additional copy of p53 (super-p53 mice) are 
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more resistant to cancer compared with wild-type mice with only two copies of 
p53 [234].  
The role of p53 in aging has been explored more recently. Accelerated 
aging and a reduced life span was seen in mice with seen in mice with a mutant 
‘m’ allele of p53 that has the ability of augment the tumor suppressor function of 
p53 [235]. The p53m allele lacks the first 6 exons of full-length p53 as well as 
some uncharacterized upstream sequences. These mice show increased 
resistance to experimentally induced and spontaneous tumors compared to both 
p53+/+ and p53+/- animals. Homozygosity of the ‘m’ allele is lethal [236]. Young 
p53+/m mice behave just like WT, but the older mice exhibit progeroid symptoms 
such as weight loss and lordokyphosis that are associated with reduced life 
spans. Tissues from the p53+/m  mice such as skin, fat, spleen, kidney and bone 
exhibit increased atrophy and decreased repair competency. This loss of 
regenerative capacity may occur due to the function of p53 in maintaining tissue 
homeostasis being compromised in the p53+/m mice due to its effect on stem cell 
activity [237]. 
Several laboratories have shown that another naturally occurring short 
isoform of p53 called ∆40p53 also causes premature aging similar to that of 
p53+/m mice, with a mean lifespan of less than 16 months compared to over 20 
months for the non-transgenic controls [238]. The ∆40p53 model is 44kDa in size 
and identical to full-length p53 except it lacks the first activator domain in the N-
terminus of the protein. The ∆40p53 mice and the p53+/m  mice show increased 
tumor suppression in the context of decreased life span. However the Super-p53 
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mice exhibit a normal aging phenotype. In all three strains increased p53 
activation results in increased expression of p21, a p53 target gene 
[235,239,238].  
While there is some evidence to support the Antagonistic Pleiotropy 
Theory, much has to be done to prove it conclusively true. We are interested in 
studying the veracity of this theory as it applies to cellular senescence. Therefore 
we have manipulated the expression of a key senescence regulator, Smurf2, in 
vivo and tested its effects on cancer and aging. The final portion of this chapter 
will focus on Smurf2 and its role in senescence and other functions.  
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Smurf2 
 
Smurf2 is a HECT domain E3 ubiquitin ligase. HECT E3 ligases are found across 
species ranging from yeast to human. They all contain a catalytic HECT 
(homologous to E6AP C-terminus) domain that comprises of roughly 350 amino 
acids and is similar to the E6AP C-terminus [240,241]. The HECT domain 
contains a conserved cysteine residue via which it catalyzes the interaction of the 
E2 ubiquitin conjugating enzyme with the protein that is targeted for 
ubiquitination. It mediates the formation of a thioester bond between the target 
protein and ubiquitin leading to the protein being marked for proteasome-
mediated degradation [240,241]. The HECT domain represents the catalytic 
domain of the E3 ligase [240,241] but substrate specificity is determined by the 
N-terminus of the protein. HECT E3 ligases are grouped into 3 different sub-
types based on distinct N-terminal amino acid motifs. These include, the HECT 
E3 with RLDs (RCC1-like domains) that are called HERC (HECT and RCC-like 
domain E3s) [242] and HECT E3s that contain WW domains. (called NEDD4 or 
NEDD4-like E3s) A third group is composed of E3s that contain neither the RLD 
nor the WW domains called as SI(ngle) E3s. HECT domain E3 ligases have 
been associated with several human diseases including cancer [243].  
Smurf2 is a WW-domain containing NEDD4-like HECT domain E3 
ubiquitin ligase. Smurf2 was identified along with its homolog Smurf1 in a yeast-
2-hybrid screen wherein WW domain containing proteins that interact with the 
PY-containing protein Smad1 which is a component of the TGF-β signaling 
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pathway [244]. Smurf2 has a N-terminal C2 domain that mediates membrane 
localization, two WW domains that recognize proline-rich motifs of substrates or 
adaptor proteins for interactions, and a large C-terminal HECT domain with a 
catalytic cysteine residue at position 716, which catalyzes the formation of the 
isopeptide bond with the C-terminus of ubiquitin and the substrate Lysine residue 
[244]. 
Work from our lab has shown that apart from functioning as an E3 ligase, 
Smurf2 also plays an important role in regulating cellular senescence. I will first 
describe how Smurf2 functions to regulate senescence and then focus on the 
known targets of Smurf2-mediated ubiquitination.  
 
Smurf2 as a regulator of Cellular Senescence: 
Smurf2 was identified as a component of a gene expression signature 
characteristic of telomere-dependent senescence in human fibroblasts [11]. The 
up-regulation of Smurf2 in replicatively senescent cells is readily distinguishable 
its expression in cycling and or quiescent cells. Further the overexpression of 
Smurf2 in early passage human fibroblast cells resulted in the induction of 
senescence [245]. This induction of senescence is independent of Smurf2’s E3 
ligase activity, (the C716A E3 ligase mutant of Smurf2 induces senescence 
effectively) and is dependent on both the p53 and the Rb pathways [245]. 
Further, it was shown that Smurf2 regulates p21 independent of its ligase activity. 
Deletion of the C2 domain does not affect the senescence induction function of 
Smurf2 [245]. Recently, work from our lab has shown that Smurf2 targets ID1 
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(Inhibitor of differentiation 1) for ubiquitin-mediated degradation [246]. The 
inhibitor of differentiation or DNA binding (Id) family of transcription regulators 
plays an important role in cell proliferation, differentiation, and senescence [247-
249]. ID1 is known to inhibit p16 expression by sequestering the bHLH factor 
E47, and preventing the transactivation of p16 [250,251]. Further, ID1 has been 
shown to be a key regulator of replicative senescence. Inhibition of ID1 
expression activates the senescence response [250,251] and overexpression of 
ID1 delays senescence [252-256]. Work from our lab has shown that Smurf2 
targets ID1 for ubiquitin-mediated degradation and thus regulates p16 expression 
in senescence [246]. Thus, the ligase-independent regulation of p21 (and the p53 
arm of the senescence pathway) and the ligase dependent regulation of p16 (and 
the pRb arm of the senescence pathway) provide a mechanism for Smurf2’s 
function of inducing senescence by regulating both of the major senescence 
pathways.  
 
Targets of Smurf2-mediated ubiquitination: 
Several targets of Smurf2-mediated ubiquitination play important roles in 
biologically important processes such as cell-cycle progression, tumor 
suppression and promotion and cell migration and invasion. These include 
various components of the TGF-ß signaling pathway, such as Smad1 [257], 
Smad2 [258], TGF- βR-I [259], TGF-βR-II [260] and SnoN, a transcriptional co-
repressor of the TGF-β signaling pathway [261]. Recently, Smurf2 has also been 
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shown to monoubiquitinate Smad3 and prevent the formation of Smad3 
complexes that further inhibit TGF- β signaling [262]. 
Smurf2 has also been shown to be the E3 ubiquitin ligase for the GTPase 
Rap1B [263], the RING-H2 protein RNF-11 [264], the Runt domain transcription 
factors Runx3 [265] and Runx2 [266]. Smurf2 is also known to ubiqutinate 
components of the Wnt signaling pathway such as β -Catenin [267] and Axin 
[268]. 
Smurf1, a homolog of Smurf2 is another known target of Smurf2-mediated 
ubiquitination, and this ubiquitination leads to migration of breast cancer cells 
[269]. Smurf2 has also been shown to ubiquitinate the adaptor protein NEDD9 
and target it for proteasome-mediated degradation. NEDD9 localizes to the 
centrosome and is essential for activation of the Aurora-A kinase in mitosis [270]. 
Aurora-A activation during late G2 is a critical step for commitment to mitosis and 
Smurf2 depletion leads to delayed entry into mitosis.  
The TGF-β signaling pathway is known to play a role in several important 
processes such as proliferation, differentiation, apoptosis, adhesion, invasion, 
and cellular micro-environment [271-273]. It has also been shown to play 
important roles in cancer. Analysis of human tumor samples has shown that 
immunostaining for TGF-β correlates with metastasis in breast, colon, and 
prostate cancer [274-276]. Further, the intensity of TGF-β staining was found to 
be higher in the metastatic lesions than the primary tumors in breast, colon and 
prostate cancer [277,278]. The TGF-β signaling pathway has both tumor-
suppressive and tumor-promoting functions [279]. Runx2 is known to be 
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abnormally expressed in tumors that metastasize to bone. RNF11 is 
overexpressed in breast and pancreatic tumors [264]. The Wnt signaling pathway 
is known to play a role in several important processes ranging from embryonic 
development to cancer. 
Interestingly, Smurf2 has been shown to promote the degradation of p53 
by stabilizing MDM2 by enhancing its heterodimerization with MDMX [280]. 
Further, Smurf2 has also been shown to promote the stabilization of EGFR by 
ubiquitinating it and protecting it against c-Cbl-mediated degradation [281]. Gene 
expression microarray data from patients showed a strong correlation of 
expression between EGFR and Smurf2 suggesting that Smurf2-mediated 
protective ubiquitination of EGFR may be responsible for EGFR overexpression 
in tumors [281].  
Thus several targets of Smurf2-mediated ubiquitination are known to play 
an important role in cancer development and progression making it a potentially 
important player in the regulation of these processes.  
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Smurf2 regulates the senescence response and 
suppresses tumorigenesis in mice 
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Abstract 
 
The E3 ubiquitin ligase Smurf2 mediates ubiquitination and degradation of 
several protein targets involved in tumorigenesis and induces senescence in 
human cells. However, the functional role of Smurf2 in tumorigenesis has not 
been fully evaluated. In this study, we generated a mouse model of Smurf2 
deficiency to characterize the function of this E3 ligase in tumorigenesis. Smurf2 
deficiency attenuated p16 expression and impaired the senescence response of 
primary mouse embryonic fibroblasts. In support of a functional role in controlling 
cancer, Smurf2 deficiency increased the susceptibility of mice to spontaneous 
tumorigenesis, most notably B cell lymphoma. At a premalignant stage of 
tumorigenesis, we documented a defective senescence response in the spleens 
of Smurf2-deficient mice, consistent with a mechanistic link between impaired 
senescence regulation and increased tumorigenesis. Taken together, our 
findings offer genetic evidence of an important tumor suppressor function for 
Smurf2. 
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INTRODUCTION 
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The E3 ubiquitin ligase Smurf2 has been shown to mediate ubiquitination of 
several proteins, including components of the TGF-β and Wnt signaling, Runx2, 
Rap1B, Smurf1 and Id1 [259,258,257,267,266,263,269,282,283,268,246]. These 
diverse substrates suggest that Smurf2 is involved in many biological processes. 
We have previously shown that Smurf2 expression increases in response to 
telomere shortening in senescent cells [11]. Furthermore, we have discovered 
that Smurf2 recruits both the p53 and pRb pathways to activate senescence 
[245], suggesting that Smurf2 is a critical regulator of senescence. As an 
important tumor suppression mechanism, senescence restricts the proliferation 
of cells at risk of malignant transformation [107,83]. Consistent with this model, 
we have found that up-regulation of Smurf2 leads to growth arrest in various 
tumor cells [284].  
Despite the advance in our understanding of Smurf2’s molecular function, 
the precise role of Smurf2 in tumorigenesis has not been established. In this 
study, we generated a mouse model of Smurf2 deficiency, and showed that 
Smurf2 deficiency leads to an impaired senescence response in primary cells. 
Consistent with its function in senescence regulation, Smurf2-deficient mice 
exhibited increased spontaneous tumorigenesis, indicating that Smurf2 functions 
as a tumor suppressor. 
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RESULTS 
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A mouse model of Smurf2 deficiency 
We used a mouse embryonic stem (ES) cell line RRA098 with a gene-trapping 
vector (pGT1lxf) inserted into intron 1 of Smurf2 (Fig.2.1a) to generate a mouse 
model of Smurf2 deficiency. A single integration of the trapping vector in RRA098 
genome was observed in Southern analysis (Fig.2.1b), and further determined by 
sequencing analysis (Fig.2.1c and data not shown). Smurf2 transcripts were 
increased in ES cells after Cre-mediated excision of loxP-flanked splicing 
acceptor (SA) (Fig.2.1d), indicating that Smurf2 expression is compromised in 
RRA098 cells, and removal of SA restores its expression.  
Mice heterozygous for the trapped allele (Smurf2+/T) were viable and 
developmentally normal. Intercrossing of Smurf2+/T mice generated Smurf2T/T 
mice with expected Mendelian frequency (36:72:35 for 
Smurf2+/+:Smurf2+/T:Smurf2T/T) and grossly normal development (Fig.2.2). 
Smurf2 expression in Smurf2+/T MEFs or embryos was reduced to ~50% of wild-
type, whereas Smurf2 (~20%) was still detected in Smurf2T/T MEFs or embryos 
(Fig.2.3a), suggesting that this trapped allele is hypomorphic. Consistent with this 
notion, Smurf2 expression was reduced but not absent in many tissues of 
Smurf2T/T mice compared to wild-type littermates (Fig.2.3b). The Smurf2T/T 
mouse thus serves as a model of Smurf2 deficiency. 
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Fig.2.1: Characterization of a mouse model of Smurf2 deficiency. (a) 
Schematics of the trapped Smurf2 allele. En2-1: mouse En2 intron 1; SA: splicing 
acceptor; pA: SV40 polyadenylation signal. (b) Southern analysis of genomic 
DNA of RRA098 cells or Smurf2+/T mouse tail using Neo as a probe. Specific 
bands are indicated by arrows at left with DNA ladder at right. (c) The integration 
site of the gene-trapping vector is determined by genomic PCR using primer 
En2-1 and one of the 12 primers (P1-P12) in the intron 1 of Smurf2. (d) Elevated 
Smurf2 expression in Cre-expressing ES clones, which were identified by 
genomic PCR with primers P1 and P2 shown in (a).  
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Fig.2.2: Smurf2-deficient mice exhibit normal development. H&E staining of 
tissues from 2-month old wild-type (+/+) and Smurf2T/T (T/T) mice shows a 
normal development of Smurf2-deficient mice. Scale bar is 200 µm for 10X 
images and 100 µm for 50X images. 
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Fig.2.2 
 
 
 
 
44
Fig.2.3: The Smurf2-deficient mouse model is a hypomorph. (a) Smurf2 
expression in wild-type (+/+), Smurf2+/T (+/T) and Smurf2T/T (T/T) MEFs and 
embryos analyzed by Western (both) and quantitative RT-PCR (MEFs only). 
Smurf2 expression in wild-type was set as 100% after normalization with β-actin. 
Error bars were standard deviations of three independent experiments. (b) 
Smurf2 expression in tissues of 2-month-old wild-type and Smurf2T/T littermates. 
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Fig.2.3 
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Impaired senescence response in Smurf2-deficient MEFs 
At early passage, no obvious difference in cell proliferation was noted among 
MEFs of different genotypes (Fig.2.4a). However, senescence entry was delayed 
in Smurf2T/T and Smurf2+/T MEFs compared to wild-type (Fig.2.4b). We next 
passaged MEFs with a 3T9 protocol starting from passage 2. Wild-type MEFs 
entered senescence around passage 7. In contrast, Smurf2T/T and even some 
Smurf2+/T MEFs showed a tendency to become immortalized and continued to 
proliferate beyond passage 20 (Fig.2.4c), indicating that Smurf2 deficiency 
promotes spontaneous immortalization of primary fibroblasts. 
To assess whether immortalization of Smurf2T/T MEFs is the result of 
Smurf2 deficiency or caused by secondary mutations in other genes, we tested 
whether Smurf2 can induce senescence in these MEFs. Ectopic expression of 
Smurf2 or a ligase mutant C716A [245] induced senescence in early passage 
and late passage already immortalized Smurf2T/T MEFs (Fig.2.5a), suggesting 
that Smurf2 is essential for senescence. Furthermore, we found that p53 and 
p21CIP1/WAF1 (p21) increased in early passage and immortalized Smurf2T/T MEFs 
after doxorubicin treatment (Fig.2.5b), indicating that Smurf2-deficient MEFs 
have a functional DNA damage response, and immortalization of Smurf2T/T MEFs 
is independent of p53 loss.  
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Fig.2.4: Impaired senescence response in Smurf2-deficient MEFs. (a) Cell 
proliferation and (b) Senescence analyses in early passage (P2) wild-type (+/+), 
Smurf2+/T (+/T) and Smurf2T/T (T/T) MEFs. Student t-test was used in pair-wise 
comparison with statistical significance indicated as: * (P<0.05), ** (P<0.01), and 
*** (P<0.001). (c) Immortalization assay of MEFs starting from passage 2 with 
population doubling (PD) set as 0. 
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Fig.2.4 
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Fig.2.5: Smurf2-deficient MEFs enter senescence in response to Smurf2 
overexpression and have a normal p53 pathway. (a) Early passage (P4) and 
late passage (P28) already immortalized Smurf2T/T (T/T) MEFs were stained with 
crystal violet and for senescence-associated β -galactosidase (SA-β-gal) activity 
following ectopic expression of Smurf2, ligase mutant C716A or GFP control. (b) 
Western analysis of p53 and p21 in MEFs following doxorubicin treatment. 
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Fig.2.5 
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To further investigate the mechanism underlying the impaired senescence 
response in Smurf2-deficient MEFs, we examined the expression of known 
senescence regulators during serial passage. No obvious change in the 
expression of p19Arf (p19), p21 or p53 was observed between wild-type and 
Smurf2T/T MEFs (Fig.2.6). Consistent with our recent finding that Smurf2 
regulates p16INK4a (p16) expression through ubiquitination of Id1 [246], p16 
expression in early passage Smurf2T/T MEFs was decreased compared to wild-
type MEFs. While p16 expression was elevated in late passage wild-type MEFs, 
this p16 elevation was significantly attenuated in Smurf2T/T MEFs (Fig.2.6), 
suggesting a mechanistic link between inhibition of p16 expression and delayed 
senescence in Smurf2-deficient MEFs. 
 
Increased spontaneous tumorigenesis in Smurf2-deficient mice 
Smurf2T/T (30.6%) and Smurf2+/T (23.8%) mice developed tumors spontaneously 
within 20 months, whereas no tumor was found in wild-type mice within the same 
period (Fig. 3A). All affected Smurf2-deficient mice had enlarged spleens 
(Fig.2.7a) and developed lymphomas. A majority of lymphomas (82.4%) stained 
strongly for B220 (Fig.2.7b), indicating a B-cell origin. The lymphomas often 
spread to other organs: 47.1% and 23.5% of mice with lymphoma in spleen were 
found to have lymphoma in kidney and liver, respectively (Fig.2.7b). In addition to 
lymphoma (72.7% of tumors), we also found other types of tumors, including 
hepatocellular carcinoma (13.6%), adenocarcinoma in small intestine (4.5%) and 
sarcoma (9.1%) (Fig.2.7c). Collectively, these results indicate that Smurf2 
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deficiency leads to increased spontaneous tumorigenesis in mice, and suggest 
that Smurf2 functions as a tumor suppressor.  
Increased spontaneous tumorigenesis was also observed in Smurf2+/T 
mice, which had ~50% of Smurf2 protein. Interestingly, three of the four 
lymphoma samples from Smurf2+/T mice showed lower level of Smurf2 protein 
than normal spleen of Smurf2+/T mice (Fig.2.8a). To test whether loss of 
heterozygosity occurred during development of these lymphomas, we used 
quantitative PCR to compare the abundance of the wild-type and trapped Smurf2 
alleles with GAPDH in tail and spleen (Fig.2.8b). Three lymphoma samples from 
Smurf2+/T mice with decreased Smurf2 protein levels showed a reduction in the 
abundance of the wild-type Smurf2 allele compared to unaffected corresponding 
tail DNA (Fig.2.8b), whereas the relative abundance of the trapped Smurf2 allele 
was either unchanged or increased (Fig.2.8c). These results suggest a loss of 
the wild-type Smurf2 allele in these lymphomas, and confirm that loss of Smurf2 
results in the formation of tumors in mice. 
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Fig.2.6: Impaired senescence response in Smurf2-deficient MEFs. Western 
analysis of senescence regulators in MEFs passaged in Fig.2.4(b).  
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Fig.2.6 
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Fig.2.7: Increased spontaneous tumorigenesis in Smurf2-deficient mice. (a) 
Kaplan-Meier curves of tumor-free survival of wild-type (+/+), Smurf2+/T (+/T) and 
Smurf2T/T (T/T) mice. Statistical significance was analyzed by the log-rank test. 
(b) Representative spleens of a moribund Smurf2T/T mouse and an age-matched 
wild-type mouse. (c) Representative H&E and B220 staining of lymphomas in 
spleen, liver and kidney of Smurf2T/T mice, in comparison to sections of wild-type 
mice. (d) Representative H&E staining of other types of tumors found in Smurf2-
deficient mice. Scale bars for 10x and 50x images are 200 µm and 100 µm, 
respectively. 
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Fig.2.7 
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Fig.2.8: Analysis of loss of heterozygosity in lymphomas derived from 
Smurf2+/T (+/T) mice. (a) Western blot of Smurf2 expression in lymphomas from 
Smurf2+/T and Smurf2T/T mice. Smurf2 expression in spleens of 2-month old wild-
type (+/+), Smurf2+/T (+/T) and Smurf2T/T (T/T) mice is shown for comparison. 
Quantitation of abundance of (b) the wild-type Smurf2 allele and (c) the trapped 
Smurf2 allele after normalization with the GAPDH allele in tail and spleen DNA of 
2-month old wild-type (+/+), Smurf2+/T (+/T) and Smurf2T/T (T/T) littermates. The 
relative level of the wild-type Smurf2 allele in +/+ and the relative level of the 
trapped Smurf2 allele in T/T mice were set to be 1. Quantitation of abundance of 
(d) the wild-type Smurf2 allele and (e) the trapped Smurf2 allele after 
normalization with GAPDH in DNA from lymphomas of Smurf2+/T (+/T) mice and 
their corresponding tail DNA. The relative level in tail DNA was set to be 1. 
Lymphoma samples analyzed in (d) and (e) correspond to those shown in (a). 
Error bars were calculated from standard deviations of three independent 
experiments. 
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Fig.2.8 
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Senescence regulation in spleens of Smurf2-deficient mice 
As the majority of tumors found in Smurf2-deficient mice were B-cell lymphomas 
in spleen, we investigated whether the senescence response was impaired in 
spleens of Smurf2-deficient mice. In 12-month-old premalignant mice, we found 
positive staining for SA-β-gal activity in spleens of wild-type mice, whereas such 
positive staining was largely absent in spleens of Smurf2T/T mice (Fig.2.9a), 
indicating an impaired senescence response in spleens of Smurf2-deficient mice. 
Consistent with our recent finding that Smurf2 regulates p16 expression through 
ubiquitination and degradation of Id1 during senescence [246], we found that Id1 
was elevated, while p16 expression was decreased in spleens of 12-month-old 
premalignant Smurf2T/T mice compared to age-matched wild-type littermates 
(Fig.2.9b). These results suggest that the Smurf2-Id1-p16 axis regulates 
senescence in vivo. As senescence acts as an important tumor suppressor to 
restrict the proliferation of cells at risk of malignant transformation [107,83], an 
impaired senescence response in Smurf2-deficient cells provides an underlying 
mechanism of increased spontaneous tumorigenesis in Smurf2-deficient mice. 
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Fig.2.9: Impaired senescence response in spleens of aged Smurf2-deficient 
mice. (a) Representative staining for SA-β-gal activity and quantitation (10 
randomly selected fields) in spleens of 12-month-old premalignant wild-type (+/+) 
and Smurf2T/T (T/T) mice. (b) Western and quantitative RT-PCR analyses of p16 
expression in spleens of 12-month-old mice. The relative expression of p16 in 
wild-type was set to be 1 after normalization with β-actin. Error bars were 
standard deviations of three independent experiments. Student t-test was used in 
statistical analysis (*:P<0.05, **:P<0.01 and ***:P<0.001). 
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Fig.2.9 
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In this study, we found that Smurf2-deficient mice exhibited an increased 
susceptibility to spontaneous tumorigenesis, indicating that Smurf2 has a tumor 
suppression function. Further support for Smurf2 as a tumor suppressor is the 
observation of increased spontaneous tumorigenesis in Smurf2+/T mice 
accompanied by frequent loss of the wild-type Smurf2 allele in these tumors. 
Another group has also independently reported similar findings using a Smurf2 
knockout mouse model [285]. Consistent with the notion that Smurf2 is a tumor 
suppressor, Smurf2 mutations have been found in human melanoma (2 out of 8) 
and lung carcinoma (1 out of 145) samples in COSMIC database 
(http://www.sanger.ac.uk/genetics/CGP/cosmic). The identified nonsense 
mutations (1222C>T, R408* or 1774C>T, R592*) would result in truncated 
Smurf2 proteins lacking a functional HECT domain, thus disrupting its function as 
an E3 ubiquitin ligase and its ability to induce senescence [245]. Collectively, 
these observations support the notion that Smurf2 is a tumor suppressor.  
Increased tumorigenesis was preceded by an impaired senescence 
response in spleens and primary fibroblasts of Smurf2-deficient mice. Consistent 
with our recent finding that Smurf2 ubiquitinates Id1 to regulate p16 expression 
during senescence in culture [246], we found elevation of Id1 and corresponding 
decrease in p16 expression in spleens of premalignant Smurf2-deficient mice, 
suggesting that the Smurf2-Id1-p16 axis regulates senescence response in vivo. 
Emerging evidence indicate that senescence is an important tumor suppression 
mechanism by restricting proliferation of cells at risk of neoplastic transformation 
[107,83]. Our current study provides a mechanistic link between Smurf2-
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mediated senescence regulation and its role as a tumor suppressor in vivo.  
Smurf2 is suggested to target Smads and TGF-β receptor for 
ubiquitination and degradation [259,258,257]. However, these cell culture studies 
are challenged by recent studies of Smurf2 knockout mice, which indicate that 
Smurf2 does not regulate protein stability of Smads and TGF-β receptor under 
physiological conditions in vivo [262,283]. Smurf2 has also been implicated to 
ubiquitinate both negative (Axin and GSK-3β) and positive (β-catenin) regulators 
of the canonical Wnt signaling pathway [268,267,282]. Studies of Smurf1/2 
double knockout mice reveal that Smurf2 instead regulates the non-canonical 
Wnt signaling through ubiquitination of Prickle1 [283]. We have recently 
discovered that Smurf2 ubiquitinates Id1 [246], which is involved in diverse 
cellular processes including proliferation, differentiation and angiogenesis [249]. 
It will be interesting to determine whether Smurf2-mediated ubiquitination of any 
of these or other yet unidentified protein substrates, in addition to senescence 
regulation, plays an important role in its function as a tumor suppressor.  
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Materials and Methods  
Smurf2-deficient mice 
Mouse ES cell line RRA098 was purchased from Mutant Mouse Regional 
Resource Center at University of California-Davis. ES cells were injected into 
C57BL/6 blastocysts to obtain chimeric mice, which were bred to generate 
Smurf2-deficient mice. Mouse cohorts on a mixed 129OlaxC57BL/6 background 
were monitored, and moribund mice were sacrificed for necropsy. Paraffin-
embedded tissue sections were stained for Hematoxylin & Eosin and B220 
(Abcam). Frozen sections were fixed, stained for senescence-associated β-
galactosidase (SA-β-gal) activity [245] and counterstained with Eosin. Mouse 
studies were approved by the Institutional Animal Care and Use Committee of 
University of Massachusetts Medical School. 
 
Assays of mouse embryonic fibroblast (MEFs)  
MEFs were prepared from E12.5 embryos and cultured as described [286]. To 
analyze cell proliferation, MEFs were seeded in 6-well plates, harvested in 
triplicate and counted daily using a Particle Counter (Beckman Coulter). In 
senescence assay, MEFs were plated in 10-cm dish, and subcultured every 3 
days before they reached high cell density. In 3T9 immortalization assay, MEFs 
were plated at 3x106 per 10-cm dish in triplicate and passaged every 3 days.  
MEFs were infected with lentivirus expressing Smurf2 or GFP as 
previously described [284], and stained with crystal violet or SA-β-gal activity 
[245] after selection with puromycin. To analyze DNA damage response, MEFs 
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were treated with 1 µM doxorubicin (Sigma), and cell lysates were collected for 
Western blotting.  
 
Southern blotting 
Genomic DNA was extracted using genomic DNA isolation kit (Lamda Biotech), 
digested with restriction enzymes (New England Biolabs), electrophoresed in 
agarose gel and transferred to Hybond nylon membrane (GE Healthcare). Probe 
labeling, hybridization and detection were carried out using DIG-high prime DNA 
labeling and detection starter kit (Roche). 
 
Quantitative PCR 
Total RNA was isolated using RNeasy Mini kit (Qiagen), and reverse-transcribed 
using Superscript II (Invitrogen). Real-time PCR was carried out using SYBR 
Green PCR kit (Bio-Rad) with the following primers: Smurf2 (5’-
ATGAAGTCATTCCCCAGCAC-3’; 5’-AACCGTGCTCGTCTCTCTTC-3’), p16 (5’-
CGAACTCTTTCGGTCGTACCC-3’; 5’-CGAATCTGCACCGTAGTTGAG-3’) or β-
actin (5’-GCTCTTTTCCAGCCTTCCTT-3’; 5’-GTGCTAGGAGCCAGAGCAGT-
3’). 
Genomic DNA was used in real-time PCR to determine the relative 
abundance of the Smurf2 alleles with the following primers: wild-type Smurf2 (5’-
GAGGGTGTTGGTGAGAGGAA-3’; 5’-TTACACAGCATCTGGCAAGG-3’), 
trapped Smurf2 (5’-GAGGGTGTTGGTGAGAGGAA-3’; 5’-
GACAAGTAGATCCCGGCGCTC-3’) or GAPDH (5’-
67
AGCCTTAAAAGCCCTTGAGC-3’; 5’- CTAGGAAGAGGGGGAGAGGA-3’). 
 
Western blotting 
Western blotting was carried out as described [246] with the following antibodies: 
Smurf2 (Epitomics), p53 (Calbiochem), α-tubulin (Sigma), p16, p19, p21 and 
GAPDH (Santa Cruz Biotechnology).  
 
Statistical analyses 
Kaplan-Meier survival curves were plotted and analyzed with the log-rank test. 
Student t-test (two-tailed and unpaired) was used for pair-wise comparisons.  
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CHAPTER III 
 
 
Smurf2 mediates ubiquitination of YY1 to regulate c-Myc 
expression and suppresses B-cell lymphomagenesis in 
mice 
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ABSTRACT 
 
We have shown previously that Mice deficient in Smurf2 exhibit increased 
susceptibility to spontaneous tumorigenesis with the majority of tumors being B-
cell lymphomas in spleen.  In this chapter, we characterized these lymphomas 
and determined that they were derived from germinal centers and had a 
phenotype resembling human diffuse large B-cell lymphoma (DLBCL). We found 
that these lymphomas were associated with enhanced proliferation and elevated 
expression of c-Myc in splenic B cells. We discovered that Smurf2 interacted with 
and mediated ubiquitination of YY1. Stabilization of YY1 in Smurf2-deficient cells 
up-regulated c-Myc expression and enhanced cell proliferation. The Smurf2-YY1-
c-Myc regulatory axis represents a novel mechanism by which Smurf2 
suppresses cell proliferation and lymphomagenesis. Furthermore, low level of 
Smurf2 expression is observed in primary human DLBCL samples and correlates 
with poor survival prognosis in DLBCL patients, suggesting that Smurf2 is a 
potential therapeutic target for DLBCL. 
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We have shown in Chapter 2 that Smurf2 may function as a tumor suppressor in 
vivo by regulating the senescence response. The Smurf2-deficient mice develop 
tumors spontaneously, and 70% of these tumors are lymphomas. The 
lymphomas were B-cell derived and were diagnosed as Diffuse Large B-cell 
Lymphomas (DLBCL), which accounts for 30-40% of newly diagnosed 
lymphomas and is the most common type of Non-Hodgkin’s Lymphoma [287]. 
Current chemotherapy regimens can cure only 40-50% of patients, and this has 
been attributed to the fact that DLBCL comprises of a heterogeneous group of 
cancers [288]. Gene expression profiling has divided DLBCL into 3 molecular 
subtypes that are histologically tantamount. These include, the Activated B-Cell 
Like (ABC), the Germinal Center B-Cell like (GCB) and the Primary Mediastinal 
B-Cell Lymphoma (PMBL) [289-292]. These subtypes differ in gene expression 
as well as the cell of origin, each of them arising from distinct molecular 
processes that ultimately lead to neoplastic transformation. Significant progress 
has been made in our understanding of the various dysregulated pathways and 
genetic anomalies that govern the development of these lymphomas [293,294], 
however a sizable fraction of DLBCL are still incurable, suggesting that further 
understanding in the pathogenesis of this disease is needed in order to develop 
more specific therapeutic approaches.  
A lot of interest in the DLBCL field has focused on the ABC-type of 
lymphoma and much is known about the molecular pathways deregulated in this 
sub-type of DLBCL [295-299]. Less is known about the lesions governing the 
GCB-type DLBCL, and most of the research in this field has focused on the 
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dysregulated expression of BCL6 and its target genes in these tumors [300-303]. 
In this chapter we show that the lymphomas in the Smurf2-deficient mice are 
GCB-type DLBCL, thus providing novel insight into the pathogenesis of these 
tumors. Further, we have determined that c-Myc is upregulated in the lymphomas 
as well as normal spleens from the Smurf2-deficient mice. We also show that 
Smurf2 acts as an E3 ligase for YY1, targeting it for proteasome-mediated 
degradation. YY1 is a transcription factor that has been previously shown to 
regulate c-Myc [304,305]. We demonstrate that YY1’s regulation of c-Myc is 
dependent on Smurf2 expression in a lymphoma cell line in culture. We propose 
that the Smurf2-mediated ubiquitination of YY1 and its regulation of c-Myc is a 
potential mechanism by which the Smurf2-deficient mice develop GCB-type 
DLBCL.  
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Germinal center (GC)-derived lymphomas in Smurf2-deficient mice 
Previously we have shown that Smurf2-deficient mice exhibit increased 
susceptibility to spontaneous tumorigenesis, with the majority of tumors found in 
spleen. Hematoxylin & Eosin (H&E) staining, B220 staining and histopathological 
analysis of spleen sections of affected Smurf2T/T or Smurf2+/T mice indicate that 
these mice developed lymphomas with a B-cell origin and a phenotype 
consistent with DLBCL and/or Burkitt’s lymphoma [306] (Chapter 2).  Further 
analyses found that these lymphomas stained positively for the GC marker 
peanut agglutinin (PNA) (Fig.3.1a), suggesting that these lymphomas were likely 
GC-derived. Consistent with this notion, we observed an expansion of IgDnegIgMlo 
B cells that were CD23 negative and stained strongly for CD24 in representative 
lymphomas (Fig.3.1b). Furthermore, these lymphomas underwent class switch 
recombination to IgG2a (Fig.3.2) and exhibited increased somatic hypermutation 
in the immunoglobulin heavy chain (IgH) locus (Table 3.2). Collectively, these 
data indicate that lymphomas developed in Smurf2-deficient mice are GC-
derived.  
When splenic cells from tumor-bearing mice were injected into 
Recombination Activating Gene 1 knockout (Rag1-/-) mice, Rag1-/- recipient mice 
became moribund 6 weeks after injection. A further expansion of the IgDnegIgMlo 
B cells was observed in the spleens of Rag1-/- recipients (Fig.3.3). Furthermore, 
these IgDnegIgMlo B cells stained positively for CD24 and CD95, consistent with a 
germinal center-derived phenotype (Fig.3.3). Positive staining for IgG2a further 
confirmed that these tumors underwent class switch recombination (Fig.3.3).   
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Fig.3.1: Smurf2-deficient mice develop GCB-type lymphomas.  
 
(a) Representative H&E and PNA staining of sections of lymphomas in spleen of 
Smurf2T/T mice. Staining of tissue sections of wild-type mice is shown for 
comparison. Scale bar for 10x images is 200 µm, and scale bar for 50x images is 
100 µm. (b) FACS analyses of splenic B cells from two matched pairs of 
lymphoma-bearing Smurf2T/T (T/T) and age-matched wild-type mice are 
presented. Live cells are displayed (propidium iodide excluding). CD19 positive 
cells (left panel) are gated and then displayed in the middle panel. IgMloIgDlo cells 
are gated and displayed in the right panel. CD23-CD24+ cells, indicated by a gate 
in the right panel, are activated or previously activated B cells.  
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Fig.3.1 
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Fig.3.2: Smurf2-deficient lymphomas exhibit features of GCB-type 
lymphomas. Analysis of class switch recombination in representative 
lymphomas. Postswitch transcripts (γ1, γ2a, γ2b and γ3) and germline transcripts 
(µ) of mouse immunoglobulin heavy chain locus were analyzed by quantitative 
RT-PCR. Splenic cells from wild-type and AID knockout mice were used as 
controls. Relative expression in wild-type splenic cells was set to be 1 after 
normalization with β-actin. Error bars were calculated from standard deviations of 
three independent experiments. 
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Fig.3.2 
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Table 3.2: Somatic mutations in the rearranged VH186.2 transcripts of µ isotype 
in lymphomas derived from spleens of Smurf2-deficent micea 
    # chains Mutations per 103 basesb 
    Seq Mut Total (306 bp)        CDR1+2 (66 bp)                Framework 
(228 bp) 
   Total   Rc      Sc      R/Sc       Total     R         S       R/S    Total   R       
S      R/S 
WT Spd     10  8 33.0   23.9     9.1   2.6         62.1     57.6     4.5   12.8       25.9   15.4   
10.5   1.5 
42-2      6  6 61.5   48.5   13.0   3.7       108.6   103.5     5.1   20.3    50.4   34.4   
16.0   2.2  
45.6-6e      6  6 78.4   56.6   21.8   2.6       184.3   159.1   25.2     6.3     49.7   28.5   
21.2   1.3  
127-2      3  3 63.2   38.1   25.1   1.5          146.5   111.1   35.4     3.1     39.5   16.1   
23.4   0.7 
93-7      3   3 73.0   50.1   22.9   2.2          181.8   156.6   25.2     6.2    42.4   19.0   
23.4   0.8 
 
a The region that was used to determine mutation frequency corresponds to amino acid residues -
4 to 98 in VH186.2 µ transcripts. Nucleotide replacements at the VHDH junctions were not scored 
as mutations. 
b Mutation frequency was calculated by dividing the accumulated number of mutations in a given 
region with the total number of nucleotides sequenced for the region, length of which is shown in 
parentheses. 
c R and S stand for replacement and silent mutations, respectively. R/S indicates ratio of 
replacement to silent mutations. 
d Spleen from wild-type mouse. 
e A deletion of 128 bp, in addition to point mutations, was found in a clone derived from tumor 
45.6-6. This clone was not used in calculation of mutations listed in the table. 
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Fig.3.3: Tumors from Smurf2-deficient mice can be transplanted into  
RAG1-/- recipient mice. FACS analyses of splenic B cells from a lymphoma-
bearing Smurf2T/T (T/T) and a RAG1-/- recipient mouse injected with T/T spleen 
cells are presented. A wild-type (+/+) panel is provided as a control. Live cells are 
displayed (propidium iodide excluding).  Clonal expansion of the IgMloIgDlo cells 
that have been gated out of CD19+ cells are displayed in the left panel. These 
IgMloIgDlo cells stained positive for CD24 and CD95, both GC markers, as shown 
in the middle panel. These IgMloIgDlo cells also stained positive for IgG2a as 
shown in the right panel. Mice used in this experiment were between 15 and 18 
months of age.  
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Enhanced proliferation in Smurf2-deficient splenic B cells 
All tumor-bearing Smurf2T/T mice had enlarged spleens (Fig.2.7), prompting us to 
examine the spleen in pre-malignant mice. A small but statistically significant 
increase in spleen weight over body weight was found in the healthy 2-month old 
Smurf2T/T mice compared to wild-type littermates (Fig.3.4a). The frequency of 
splenic B220+ cells was found to be similar between young Smurf2T/T and wild-
type littermates (Fig.3.4b). Furthermore, flow cytometric analyses detected no 
obvious difference in the frequencies of various splenic B-cell sub-populations 
between these mice (Fig.3.4c), suggesting that B-cell differentiation is normal in 
Smurf2-deficient mice.  
Lymphomas found in Smurf2T/T or Smurf2+/T mice showed an increase in 
staining of the cell proliferation-associated antigen Ki-67, but no significant 
change in TUNEL staining for apoptosis, as compared to spleen sections of age-
matched wild-type mice (Fig.3.5a). Interestingly, Ki-67 staining was increased in 
splenic white pulps of young healthy Smurf2T/T mice as compared to wild-type 
littermates, whereas no significant change in TUNEL staining was observed 
(Fig.3.5b & c). Furthermore, increased bromodeoxyuridine (BrdU) incorporation 
was detected in non-cancerous B220+ splenic B cells or total splenic cells 
(Fig.3.5d) of young healthy Smurf2T/T mice as compared to wild-type littermates. 
These results suggest that increased cell proliferation observed in Smurf2-
deficient B cell lymphomas or splenic B cells is caused by reduced Smurf2 
expression rather than as a consequence of tumorigenesis. 
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Fig.3.4: Smurf2-deficient mice exhibit normal B-cell development and 
differentiation (a). Relative gross weight of spleen to body weight (N=12) shows 
an increase in spleen weights in Smurf2T/T (T/T) mice compared with wild-type 
(+/+). (b).Percent of B220+ cells in spleen (N=3) of 2-month-old wild-type (+/+) 
and Smurf2T/T (T/T) mice are shown. (c). FACS analysis of splenic B cells from 2-
month-old wild-type (+/+) and Smurf2T/T (T/T) mice indicates that the major 
splenic B cell populations are present at comparable frequencies. Live cells are 
displayed (propidium iodide excluding). CD19 positive cells (left panel) are gated, 
then displayed in the middle panel. The IgD++IgMint population, indicated by a 
circular gate in the middle panel, are follicular B cells. IgM++IgDlo cells are gated 
and displayed in the right panel CD93+CD24+ cells, indicated by a circular gate 
in the right panel, are immature B cells.  
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Fig.3.5: Enhanced proliferation in splenic B cells of Smurf2-deficient mice 
(a). Representative Ki-67 and TUNEL staining of lymphomas derived from 
Smurf2T/T (T/T) mice. Staining of spleen sections of aged wild-type (+/+) mice 
and an irradiated (10-Gy) mouse was shown for comparison. (b). Representative 
Ki-67 and TUNEL staining of spleen sections of 2-month old wild-type and 
Smurf2T/T mice. (c) Quantitation of Ki-67 positive cells in spleen sections of 2-
month old wild-type and Smurf2T/T mice (average of 10 randomly selected fields). 
Student t-test was used for statistical analysis. (d). Analysis of BrdU incorporation 
in B220+ splenic cells of 2-month old wild-type and Smurf2T/T mice (N=3). 
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To further analyze cell proliferation in splenic B cells, we cultured splenic cells of 
2-month old wild-type or Smurf2T/T mice with the B-cell mitogen 
lipopolysaccharide (LPS). In response to LPS, Smurf2T/T splenic B cells (B220+) 
proliferated significantly better than wild-type cells (Fig.3.5e), whereas cell 
viability was similar between them (Fig.3.5f). Using carboxyfluorescein 
succinimidyl ester (CFSE) to track cell divisions in cultured splenic B cells, we 
found that the number of Smurf2T/T splenic B cells (B220+) undergoing 
successive cell divisions was significantly increased as compared to wild-type 
cells (Fig.3.5g). Cell death was similar between wild-type and Smurf2T/T B cells 
without LPS stimulation (Fig.3.5f), consistent with our observation that apoptosis 
was unchanged in Smurf2-deficient cells. Collectively, these results indicate that 
cell proliferation is enhanced in Smurf2T/T splenic B cells, suggesting a possible 
mechanism for increased B-cell lymphomagenesis in Smurf2-deficient mice. 
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Fig.3.5 (contd): Enhanced proliferation in splenic B cells of Smurf2-
deficient mice: (e). Splenic cells from 2-month old wild-type and Smurf2T/T mice 
were cultured with or without LPS. The number of B220+ viable cells (propidium 
iodide negative) was determined by flow cytometry. Average of 3 independent 
experiments was shown. Student t-test was used for pair-wise comparison. 
(f). Viability of splenic B (B220+) cells with or without 5 µM lipopolysaccharide 
(LPS) treatment. Cell viability was determined as percent of propidium iodide 
negative B220+ cells in flow cytometry. (g). The number of B220+ cells 
undergoing different number of cell division was determined by 
carboxyfluorescein succinimidyl ester (CFSE) staining and flow cytometry. The 
ratio of the number of B220+ Smurf2T/T cells undergoing different cell divisions 
over that of wild-type cells in one representative experiment is presented. Error 
bars in (e,f) were calculated from standard deviations of at least three 
independent experiments. Statistic significance is indicated as: * (P<0.05), ** 
(P<0.01), and *** (P<0.001). 
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Elevated c-Myc expression in Smurf2-deficient mice 
Up-regulation of c-Myc is frequently observed in B-cell lymphoma, and forced 
expression of c-Myc drives lymphomagenesis in mice [307-310]. To understand 
the underlying mechanism of increased B-cell proliferation and lymphomagenesis  
we examined c-Myc expression in Smurf2-deficient mice. The expression of c-
Myc in lymphomas of Smurf2-deficient mice was increased as compared to 
spleen of aged wild-type mice (Fig.3.6a). Moreover, we found an increase in c-
Myc expression in spleen (Fig.3.6b) and liver (Fig.3.6c) of 2-month old healthy 
Smurf2T/T mice as compared to age-matched wild-type mice, suggesting that 
Smurf2 deficiency correlates with increased c-Myc expression.  
To further corroborate c-Myc elevation with Smurf2 deficiency, we 
examined the transcript levels of c-Myc transactivation targets Apex1, Cad and 
Ncl, which have been validated as c-Myc targets in multiple studies, but are not 
directly involved in cell proliferation [311]. We found increased transcript levels of 
these c-Myc targets in lymphomas as well as spleen (Fig.3.6d and e) and liver of 
young Smurf2T/T mice (Fig.3.6f).  
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Fig.3.6: Elevated c-Myc expression in Smurf2-deficient mice. 
(a). Quantitative RT-PCR analysis of c-Myc expression in lymphomas from 
Smurf2T/T (T/T) or Smurf2+/T (+/T) mice as compared to spleen of aged wild-type 
(+/+) mice. (b). Quantitative RT-PCR and Western analyses of c-Myc expression 
in spleen (b) and livers (c) of 2-month old wild-type and Smurf2T/T mice.  
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Fig.3.6 (contd): Elevated c-Myc expression in Smurf2-deficient mice. 
(d) Quantitative RT-PCR analysis of c-Myc target genes in lymphomas from 
Smurf2T/T mice as compared to spleen of aged wild-type (+/+) mice, and (e) 
Spleen and (f) Liver of 2-month old wild-type (+/+) and Smurf2T/T (T/T) mice. In 
quantitative RT-PCR analyses, the relative expression in wild-type mice was set 
to be 1 after normalization with β-actin. 
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Smurf2 mediates ubiquitination of YY1 to regulate c-Myc expression 
To investigate the underlying mechanism of Smurf2-mediated regulation of c-Myc 
expression, we searched for transcriptional regulators that have been shown to 
transactivate c-Myc and examined their potential as the ubiquitination targets of 
Smurf2. We reasoned that stabilization of such a transcriptional regulator in 
Smurf2-deficient mice could be responsible for elevated expression of c-Myc. 
YY1, which has been previously shown to transactivate c-Myc [304,312], 
contains a PPDY motif that can potentially interact with WW domains in Smurf2. 
We found that the protein levels of YY1 were increased in lymphomas derived 
from Smurf2-deficient mice (Fig.3.7a) as well as in spleens (Fig.3.7b) of young 
Smurf2T/T mice compared to wild-type littermates. In contrast, the transcript level 
of YY1 was largely unchanged in Smurf2-deficient mice (Fig.3.7b), suggesting a 
post-transcriptional regulation of YY1 by Smurf2.  
To further characterize Smurf2-mediated regulation of YY1, we stably 
expressed short-hairpin RNA (shRNA) specifically targeting Smurf2 in a human 
DLBCL cell line SUDHL-6, and found that down-regulation of Smurf2 led to an 
increase in YY1 protein (Fig.3.8a). Conversely, ectopic expression of Smurf2 
resulted in a reduction in the steady-state level of YY1 protein (Fig.3.8b). 
Consistent with the notion that Smurf2 regulates YY1 at the protein level, YY1 
transcripts were largely unchanged when Smurf2 expression was altered 
(Fig.3.8a and b). These results led us to hypothesize that Smurf2 is the E3 
ubiquitin ligase responsible for ubiquitination of YY1.  
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Fig.3.7: Smurf2-deficient mice exhibit increased YY1 protein 
(a). Western analysis of YY1 expression in lymphomas from Smurf2T/T (T/T) or 
Smurf2+/T (+/T) mice as compared to spleen of aged wild-type (+/+) mice.  
(b). Western and quantitative RT-PCR analyses of YY1 expression in spleen of 
2-month old wild-type and Smurf2T/T mice. 
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Fig.3.8: Smurf2 mediates ubiquitination of YY1 to regulate c-Myc 
expression. (a). Smurf2 expression was knocked down by shRNA or (b) Smurf2 
was ectopically expressed in human DLBCL cells SUDHL-6. The expression of 
YY1 or c-Myc was analyzed in Western and quantitative RT-PCR.  
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To test this hypothesis, we first investigated whether Smurf2 interacts with YY1, 
as the C2-WW-HECT class of E3 ligases interacts with their protein substrates to 
catalyze ubiquitination. To limit potential degradation of YY1 by Smurf2, we used 
a ligase mutant C716A, in which the conserved cysteine at residue 716 is 
replaced by alanine to abolish its E3 ligase activity [259,258,257], in co-
immunoprecipitation with YY1. Smurf2 and YY1 were found to form a complex in 
co-immunoprecipitation, whereas deletion of PPDY (ΔPY) completely abolished 
the Smurf2-YY1 interaction (Fig.3.8c). Furthermore, we found that three WW 
domains (i.e. WWs), but not C2 or HECT domain of Smurf2, were sufficient to 
interact with YY1. Deletion of the N-terminal WW domain (ΔWW1) abolished the 
interaction between Smurf2 and YY1 (Fig.3.8c). Collectively, these results 
indicate that the Smurf2-YY1 interaction is mediated by the WW domains and the 
PPDY motif. We next investigated whether Smurf2 induces ubiquitination of YY1. 
Ubiquitination of YY1, as indicated by a smear of bands, was greatly induced in 
cells expressing Smurf2 compared to GFP control, whereas catalytically inactive 
C716A lost the ability to ubiquitinate YY1 (Fig.3.8d). Collectively, these results 
indicate that Smurf2 is the E3 ubiquitin ligase responsible for ubiquitination of 
YY1. 
YY1 has been previously shown to bind to human c-Myc promoter in 
chromatin immunoprecipitation assay and up-regulate c-Myc expression 
[304,312]. We expressed shRNA to specifically knockdown YY1 expression in 
SUDHL-6 cells, and found that c-Myc transcripts were decreased upon YY1 
down-regulation (Fig.3.8e), suggesting that YY1 is required to regulate c-Myc 
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expression. Furthermore, chromatin immunoprecipitation analysis indicated that 
YY1 was bound to the c-Myc promoter in mouse spleen, and this binding was 
increased in spleen of Smurf2T/T mice compared to wild-type mice (Fig.3.8f). 
Collectively, these results suggest that stabilization of YY1 in Smurf2-deficient 
mice is responsible for the up-regulation of c-Myc. 
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Fig.3.8 (contd): Smurf2 mediates ubiquitination of YY1 to regulate c-Myc 
expression. (c). Smurf2 interacts with YY1. 293T cells were transfected with 
indicated constructs of HA-YY1 and Flag-Smurf2. Immunoprecipitation (IP) with 
anti-Flag antibody was followed by immunoblotting (IB) with anti-HA antibody. 
(d). Smurf2 ubiquitinates YY1. 293T cells were transfected with HA-YY1, 3xFlag-
Ub and Smurf2. IP with anti-HA antibody was followed by IB with anti-Flag 
antibody to detect poly-ubiquitinated YY1. (e). Knockdown of YY1 by shRNA 
leads to down-regulation of c-Myc in SUDHL-6 cells as determined by 
quantitative RT-PCR. (f). Chromatin immunoprecipitation (ChIP) assay of YY1 
binding on c-Myc promoter in spleen of 2-month old wild-type and Smurf2T/T 
mice. Fold enrichment of ChIP with anti-YY1 antibody over IgG control is shown. 
In quantitative RT-PCR analyses, the relative expression level in controls was set 
to be 1 after normalization with β-actin. Error bars were calculated from standard 
deviations of three independent experiments. Student t-test was used to 
calculate statistic significance (*: P<0.05, **: P<0.01 and ***: P<0.001). 
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Smurf2-mediated regulation of YY1 alters cell proliferation in a lymphoma 
cell line 
To understand the consequence of Smurf2-mediated ubiquitination of YY1 in 
lymphomagenesis, we investigated the Smurf2-YY1 axis in regulation of cell 
proliferation in human DLBCL cells. Consistent with our observation of increased 
cell proliferation in Smurf2-deficent mice, shRNA knockdown of Smurf2 
expression in SUDHL-6 cells led to enhanced cell proliferation (Fig.3.9a). Down-
regulation of YY1 by shRNA resulted in decreased proliferation in SUDHL-6 cells, 
suggesting that YY1 is a critical regulator of cell proliferation in DLBCL (Fig.3.9a). 
Furthermore, down-regulation of YY1 in SUDHL-6 cells that already had shRNA 
knockdown of Smurf alleviated the increase in cell proliferation mediated by 
Smurf2 deficiency (Fig.3.9a), suggesting that Smurf2 regulates cell proliferation 
through YY1. Conversely, when ectopically expressed in SUDHL-6 cells, we 
found that wild-type Smurf2, but not the ligase mutant C716A, led to significantly 
decreased cell proliferation (Fig.3.9b). Taken together, these results indicate the 
Smurf2-YY1 regulatory axis is critical in proliferation of lymphoma cells, and 
suggest a plausible mechanism underlying increased cell proliferation and 
lymphomagenesis in Smurf2-deficient mice.   
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Fig.3.9: Manipulation of Smurf2 expression alters cell proliferation in a YY1 
dependent manner.  (a). Knockdown of Smurf2 (green bar) and YY1 (blue bar) 
and double-knockdown of both Smurf2 and YY1 (pink bar) using shRNA in the 
SuDHl-6 cell line. 5*103 cells were plated in a 6-well plate and counted daily for 5 
days. Error bars are calculated from standard deviations of 3 independent 
experiments. Student t-test was used to calculate statistic significance (*: P<0.05, 
**: P<0.01 and ***: P<0.001). YY1 expression was analyzed in Western Blot. (b). 
Ectopic expression of Smurf2 and the ligase-dead C716A along with the GFP 
control in the SuDHL-6 cell line. 5*103 cells were plated in a 6-well plate and 
counted daily for 5 days. Error bars are calculated from standard deviations of 3 
independent experiments. Student t-test was used to calculate statistic 
significance (*: P<0.05, **: P<0.01 and ***: P<0.001). 
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The level of Smurf2 expression correlates with survival prognosis of 
human DLBCL patients 
To investigate whether Smurf2 deficiency has a clinical relevance in human 
lymphomagenesis, we analyzed Smurf2 expression in human primary lymphoma 
samples. In a microarray dataset (GSE2350) that contains samples of human B-
cell lymphoma and normal B cells [313], we found that the expression of Smurf2 
was decreased significantly in DLBCL, Burkitt’s lymphoma and follicular 
lymphoma as compared to normal B cells (Fig.3.10a).  
To further understand the relevance of decreased Smurf2 expression in 
human lymphomagenesis, we next investigated whether the level of Smurf2 
expression correlates with clinical outcome. Smurf2 expression was measured in 
three human B-cell lymphoma microarray datasets, each of which contains 
survival information of more than 100 patients [314-316]. Within each dataset, we 
divided lymphoma samples into four groups based on the level of Smurf2 
expression, with the 1st quartile having the lowest Smurf2 expression. Survival 
analysis of dataset GSE4475, which contains both DLBCL and Burkitt’s 
lymphoma patients [314], showed that overall survival of patients with the lowest 
Smurf2 expression (1st quartile) was significantly worse (P<0.0001) than that of 
patients with higher Smurf2 expression (2nd-4th quartile) (Fig.3.10b). Similarly, a 
significantly poor survival prognosis (P=0.0004) was observed in patients with the 
low expression of Smurf2 (1st and 2nd quartiles) compared to patients with high 
Smurf2 expression (3rd and 4th quartiles) in an independent dataset GSE10846 
(Fig.3.10c), which contains only DLBCL patients [315]. In contrast, we found no 
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significant difference in overall survival of patients in a human follicular 
lymphoma dataset [316] based on Smurf2 expression level (Fig.3.10d), 
suggesting a specific role of Smurf2 deficiency in human DLBCL and Burkitt’s 
lymphoma.  
Certain clinical and molecular parameters have been shown to predict 
DLBCL patient survival [289,291,317]. Univariate analysis indicated a significant 
correlation between poor survival prognosis and age, Ann Arbor stage, molecular 
subtype, or International Prognostic Index (IPI) score. To determine whether 
Smurf2 expression can predict clinical outcomes independent of other standard 
parameters, we carried out a multivariate Cox regression analysis, and found that 
low level of Smurf2 expression was an independent predictor of patient survival 
in both DLBCL cohorts (P=0.01 for GSE4475 and P=0.027 for GSE10846) 
(Tables 3.10a and b). 
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Fig.3.10: Smurf2 expression correlates with overall survival of human 
DLBCL patients. 
(a). Box plot representation of Smurf2 expression in normal B cells, Burkitt’s 
lymphoma (BL), DLBCL and follicular lymphoma (FL). One-way ANOVA was 
used to compare tumors with normal B cells. Statistic significance is indicated as: 
** (P<0.01) and *** (P<0.001). (b) & (c). Kaplan-Meier curves of overall survival 
of patients in human diffuse large B-cell lymphoma datasets (b) GSE4475 and (c) 
GSE10846 plotted according to the level of Smurf2 expression. The log-rank test 
was used for statistical analysis. (d). Kaplan-Meier curves of overall survival of 
patients in a follicular lymphoma dataset (http://llmpp.nih.gov/FL) [316] plotted 
according to the level of Smurf2 expression. The log-rank test was used for 
analysis. 
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Table 3.10a: Univariate and multivariate analyses of DLBCL prognostic factors 
associated with patient overall survival in cohorts GSE4475 (N=102) a. 
   Univariate analysis   Multivariate analysis 
Variable  HR (95% CI) b P  HR (95% CI) b P 
Age c   2.35 (1.41─3.92) 0.001  1.94 (0.97─3.90) 0.062 
Ann Arbor stage d 2.16 (1.28─3.65) 0.004  2.60 (1.37─4.94) 0.004 
Ki-67 score e  0.97 (0.55 ─1.72) 0.912  1.26 (0.62─2.56) 0.526 
Myc translocation f 1.11 (0.68─1.81) 0.68   1.38 (0.68─2.80) 0.379 
Subtype g  2.26 (1.34─3.82) 0.002  2.12 (1.10─4.07) 0.025 
Smurf2 h  2.68 (1.64─4.39) <0.001 2.48 (1.24─4.93) 0.01 
a Only patients with complete information in all variables were used. 
b HR: hazard ration; CI: confidence interval 
c Age: ≥60 vs. <60 years 
d Ann Arbor stage: III and IV vs. I and II 
e Ki-67 score: ≥95% vs. <95% 
f Myc translocation: presence vs. absence 
g Subtype: ABC vs. GCB 
h Smurf2: Q1 vs. Q2-Q4 
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Table 3.10b: Univariate and multivariate analyses of DLBCL prognostic factors 
associated with patient overall survival in cohorts GSE10846 (N=311) a. 
   Univariate analysis   Multivariate analysis 
Variable  HR (95% CI) b P  HR (95% CI) b P 
Age c   2.05 (1.47─2.86) <0.001 1.41 (0.94─2.11) 0.099 
Ann Arbor stage d 1.82 (1.31─2.52) <0.001 0.95 (0.61─1.47) 0.805 
Subtype e  2.81 (1.98 to 3.99) <0.001 2.17 (1.49 to 3.16)  <0.001 
Revised IPI score f 3.20 (2.31 to 4.42) <0.001 2.90 (1.84 to 4.58)  <0.001 
Smurf2 g  1.72 (1.28 to 2.42) <0.001 1.51 (1.05 to 2.18) 0.027 
a Only patients with complete information in all variables were used. 
b HR: hazard ration; CI: confidence interval 
c Age: ≥60 vs. <60 years 
d Ann Arbor stage: III and IV vs. I and II 
e Subtype: ABC vs. GCB 
f Revised IPI score: high (3, 4 and 5) vs. intermediate (1 and 2) and low (0) 
g Smurf2: Q1+Q2 vs. Q3+Q4 
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In this study, we found that Smurf2-deficient mice displayed an increased rate of 
forming GCB-type DLBCLs suggesting that Smurf2 has a tumor suppression 
function in lymphomagenesis. Increased lymphomagenesis in Smurf2+/T mice 
and frequent loss of the wild-type Smurf2 allele in lymphomas derived from these 
heterozygous mice (Chapter 2) suggest that the level of Smurf2 expression is 
important in lymphomagenesis. Consistent with these observations, we found a 
significant decrease in Smurf2 expression in human DLBCL, Burkitt’s lymphoma 
and follicular lymphoma as compared to normal B cells, indicating a clinical 
relevance of Smurf2 deficiency in human lymphomagenesis. We did not find 
evidence that the Smurf2 locus is deleted in human DLBCL [295,318] or Burkitt’s 
lymphoma [319,320], suggesting that epigenetic regulation probably plays an 
important role in Smurf2 deficiency in human lymphomagenesis. In addition, 
decreased Smurf2 expression is observed in other types of human cancer as 
compared to normal samples, including adult acute and chronic T-cell leukemia, 
B-cell chronic lymphocytic leukemia, acute myeloid leukemia and lung 
adenocarcinoma [321-324].  
Increased susceptibility to B-cell lymphomagenesis in Smurf2-deficient 
mice was associated with enhanced proliferation and elevated expression of c-
Myc in splenic B cells. An inverse correlation between Smurf2 and c-Myc 
expression is also noted in human DLBCL samples. As YY1 has been shown to 
transactivate c-Myc expression [304,312], our discovery of Smurf2-mediated 
ubiquitination of YY1 provides a novel mechanism by which Smurf2 regulates c-
Myc expression and cell proliferation. To our knowledge, Smurf2 is the first E3 
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ligase identified to ubiquitinate YY1. As a transcriptional regulator, YY1 plays a 
critical role in many biological processes including development, differentiation 
and proliferation, and has been implicated in oncogenesis [325,326]. The 
expression of YY1 is found to be increased in high-grade DLBCL or Burkitt’s 
lymphoma as compared to low grade lymphoma or normal B cells [327]. 
Furthermore, elevated YY1 expression correlates with poor survival prognosis of 
DLBCL patients [328], suggesting an oncogenic function for YY1 in human B-cell 
lymphomagenesis. YY1 is a critical regulator of B-cell development [329], and 
has been recently identified as a central regulator of the germinal center B-cell-
specific transcriptional program [330]. Consistently, our analyses of lymphomas 
generated in Smurf2-deficient mice indicate that they have a germinal center or 
post-germinal center phenotype. These results suggest that Smurf2-mediated 
ubiquitination and degradation of YY1 plays an important role in suppression of 
lymphomagenesis. 
As a master regulator of cell proliferation [331], the oncogenic function of 
c-Myc in B-cell lymphomagenesis is well documented [310,332,309,307]. Intrinsic 
tumor suppression mechanisms such as apoptosis and senescence are triggered 
by activated oncogenes to restrain the oncogenic proliferation.  With c-Myc, an 
additional layer of complexity is provided by the exquisite sensitivity of cells to 
different levels of c-Myc overexpression. High level of c-Myc overexpression 
increases cell proliferation and drives lymphomagenesis, but also induces 
apoptosis [332,309,333]. Suppression of apoptosis exacerbates c-Myc-induced 
lymphomagenesis, suggesting that apoptosis antagonizes c-Myc’s oncogenic 
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activity [309]. Further, it has been recently found that low level of c-Myc elevation 
promotes cell proliferation without inducing apoptosis [334]. Consistent with this 
observation, we found that Smurf2-deficient mice showed low level (~2-fold) of c-
Myc elevation and enhanced proliferation in B cells without significant induction 
of apoptosis. In the absence of apoptosis, senescence likely becomes the critical 
tumor suppression mechanism to antagonize the oncogenic activity of Myc. A 
recent study shows that constitutive activation of c-Myc activates senescence 
[335]. We propose that the impaired senescence response in the Smurf2 
deficient mice (Chapter 2), coupled with enhanced cell proliferation induced by 
low level of c-Myc activation drives lymphomagenesis in these mice. Smurf2 thus 
plays a dual role in tumor suppression by regulating c-Myc expression as well as 
the senescence response.   
DLBCL shows significant variations in morphology, clinical presentation 
and response to treatment. Although chemotherapy using a combination of 
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP 
plus monoclonal antibody rituximab (R-CHOP) successfully induces lengthy 
remission in 40-50% of DLBCL patients, ~30% of DLBCL patients are resistant to 
CHOP/R-CHOP treatment or relapse soon after treatment [288], indicating a 
need for additional therapeutic strategies designed to target specific molecules 
that are critical for DLBCL pathogenesis. Our finding that low level of Smurf2 
expression correlates with poor survival prognosis in DLBCL patients and 
previous observation that high level of YY1 expression correlates with poor 
survival prognosis in DLBCL patients [328] suggest that the Smurf2-YY1 
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regulatory axis is a useful predictor of clinical outcome in DLBCL patients and a 
potential therapeutic target for treatment of DLBCL.  
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MATERIALS AND METHODS 
 
 
Tumor studies:  
Mice were generated as described in Chapter 2. A mouse cohort on mixed 
C57BL/6x129Ola background was monitored until 20-month of age. Moribund 
mice were sacrificed for necropsy, and selected tissues were harvested for 
preparation of DNA, RNA and protein. Portions of each tissue were fixed in 10% 
phosphate-buffered formalin and OCT to make paraffin and frozen sections. 
Tumor sections (5 µm) were stained for Hematoxylin & Eosin, PNA (Vector 
Labs), BCL6 (Santa Cruz), Ki-67 (Leica) and TUNEL (Roche). RAG1 knockout 
mice were a kind gift from Dr. Rachel Gerstein. For the transplantation study 
2*106 tumor cells were injected retro-orbitally into sub-lethally (3Gy) irradiated 
RAG1 knockout mice using a Cesium 137 source. All mouse studies were carried 
out according to guidelines approved by the Institutional Animal Care and Use 
Committee of University of Massachusetts Medical School.  
 
Fluorescence-activated cell sorting (FACS) analysis 
Mouse spleens were collected and ground between frosted glass slides. After red 
blood cells were lysed, splenic cells were filtered through 70 µm nylon mesh and 
incubated with anti-CD16/32 antibody (Bio X Cell) for 10 min on ice to block Fc 
receptors. Cells were incubated with primary antibodies for 20 min and washed 
three times. Biotin-stained cells were incubated with streptavidin-pacific blue for 
15 min on ice and washed three times. After the final wash, cells were 
resuspended in 1 µg/ml propidium iodide (PI) to exclude dead cells. Primary 
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antibodies included CD93-Cy7PE (AA4.1), CD19-PE-TR (6D5), IgD-PE (11-26), 
IgM-APC, CD23-biotin (B3B4) and CD24-FITC (30F1), CD95-PE and IgG2A-PE. 
Antibodies and streptavidin were purchased from BD Biosciences, Invitrogen or 
eBioscience. Flow cytometry was performed on a 3-laser, 12-detector LSR II (BD 
Biosciences), and data were analyzed using FlowJo software (Treestar). 
 
Class switch recombination analysis 
Germline and postswitch transcripts of the mouse immunoglobulin heavy chain 
(IgH) locus were amplified by quantitative RT-PCR with primers as described 
[336]. Germline transcripts (µ, IgM) were amplified using primers of ImF and 
CmR. Postswitch transcripts were amplified using the following primers:  ImF and 
Cg1R for γ1 (IgG1), ImF and Cg2aR for γ2a (IgG2a), ImF and Cg2bR for γ2b 
(IgG2b), ImF and Cg3R for γ3 (IgG3). ImF: 5’-CTCTGGCCCTGCTTATTGTTG-3’; 
CmR: 5’-GAAGACATTTGGGAAGGACTGACT-3’;  
Cg1R: 5’-GGATCCAGAGTTCCAGGTCACT-3’; Cg2aR: 5’- 
GCCACATTGCAGGTGATGGA-3’; Cg2bR: 5’-
CACTGAGCTGCTCATAGTGTAGAGTC-3’; Cg3R: 5’-
CTCAGGGAAGTAGCCTTTGACA-3’. 
 
Somatic hypermutation assay 
The frequency of somatic mutation in mouse immunoglobulin heavy chain (IgH) 
locus was determined as previously described [336]. Briefly, VH186.2 transcripts 
of mouse IgH µ isotype were amplified in RT-PCR using Phusion hot start high-
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fidelity Taq Polymerase (New England Biolabs) with primers VH186.2 (5’-
ttcttggcagcaacagctaca-3’) and CmR (5’-GAAGACATTTGGGAAGGACTGACT-
3’). PCR products were cloned into pGEM-T-easy vector (Promega), and 
individual colonies were sequenced to determine the mutation frequency.  
 
Splenic B-cell proliferation assays 
Mouse spleen was collected and ground between frosted glass slides. After red 
blood cells were lysed, cells were filtered through 70 µm nylon mesh and treated 
with 10 µM carboxyfluorescein succinimidyl ester (CFSE, Invitrogen) at 37ºC for 
10 min. Cells were plated at 5x105 per well in 6-well plates and cultured in RPMI-
1640 medium supplemented with 10% fetal bovine serum (FBS, Hyclone), 2 mM 
glutamine, 100 µM MEM non-essential amino acids and 50 µM 2-
Mercaptoethanol (Invitrogen) in a humidified chamber containing 5% CO2 at 
37°C. Cells were treated with 5 µM lipopolysaccharide (LPS, Sigma) or left 
untreated as controls. Cells were collected daily for 4 days, washed with staining 
media (biotin-, flavin-, and phenol red-deficient RPMI-1640 medium, 10 mM 
pH7.2 HEPES, 0.02% sodium azide, 1 mM EDTA and 2% FBS), then stained 
with APC-conjugated anti-B220 antibody (eBioscience). After being washed and 
re-suspended in 1 µg/ml propidium iodide, cells were analyzed by flow cytometry 
using a BD FACSCaliber. Data were analyzed using FlowJo software (Treestar). 
The number of CFSE peaks was determined in order to measure the number of 
cell divisions.  
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In Bromodeoxyuridine (BrdU) incorporation assay, mice were injected with 1 mg 
BrdU (BD Biosciences) intraperitoneally. Spleen was collected 24 hours later and 
processed as described above. Splenic cells were fixed, and stained with anti-
BrdU antibody using a FITC BrdU Flow Kit (BD Biosciences) and APC-
conjugated anti-B220 antibody. Data were collected by flow cytometry using a 
BD FACSCaliber and analyzed using FlowJo software. 
 
Quantitative PCR 
Total RNA was isolated from cells or freshly dissected tissues using RNeasy Mini 
kit (Qiagen). RNA was reverse-transcribed using Superscript II (Invitrogen). Real-
time PCR was carried out on a MyiQ iCycler using a SYBR Green PCR kit (Bio-
Rad). The following primers were used: c-Myc (F: 5’-GGACAGTGTTCTCTGCC-
3’; R: 5’-CGTCGCAGATGAAATAGG-3’), YY1 (F: 5’-
TGAGAAAGCATCTGCACACC-3’; R: 5’-CGCAAATTGAAGTCCAGTGA-3’), 
Apex1 (F: 5’-GCTCCGTCAGACAAAGAAGG-3’; R: 5’-
GCATTGGGAACATAGGCTGT-3’), Cad (F: 5’-TGGTCAGTTCATCCTCACTCC-
3’; R: 5’-TACATGCCGTTCTCAGCTTG-3’), Ncl (F: 5’-
TAAGGGTGAAGGTGGCTTTG-3’; R: 5’-CCTTGTGGCTTGAAGTCTCC-3’) and 
β-actin (F: 5’-GCTCTTTTCCAGCCTTCCTT-3’; R: 5’-
GTGCTAGGAGCCAGAGCAGT-3’). 
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Western blot 
Total cell lysates were collected using RIPA buffer (50 mM Tris–HCl pH 7.5, 150 
mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid, 0.02% sodium 
azide) with freshly added complete protease inhibitors (Roche). Protein lysates 
(20 µg) were separated by SDS–PAGE Criterion X-gel (Bio-Rad) and transferred 
to nitrocellulose membranes (GE Osmonics). Immunoblots were analyzed by 
Western blotting and visualized by Western lightening chemiluminescence 
detection (PerkinElmer). Primary antibodies used in this study were Smurf2 
(Epitomics), c-Myc (Invitrogen), YY1, β-actin and GAPDH (Santa Cruz 
Biotechnology).  
 
Co-immunoprecipitation analysis 
Cells were lysed in NP40 lysis buffer (20 mM Tris–HCl, 150 mM NaCl, 2 nM 
EDTA, 1% Nonidet P-40) plus complete protease inhibitors (Roche). Lysates 
were incubated with anti-Flag M2 affinity gel (Sigma) overnight at 4°C. 
Immunoprecipitates were washed four times with NP40 lysis buffer, and analyzed 
in Western blot with anti-HA antibody.  
 
Ubiquitination assay 
293T cells were transfected with constructs that express HA-YY1 (a gift of Dr. 
Yang Shi, Harvard Medical School), 3xFlag-ubiquitin (provided by Dr. Quan Lu, 
Harvard School of Public Health) and Smurf2. GFP and C716A were used as 
controls. Cells were treated with MG132 (20 µM, Sigma) for 2 hrs before cell 
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lysis. Cells were collected in RIPA buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 
1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid, 0.02% sodium azide) plus 
10 mM N-ethylmaleimide (Fisher Scientific). Cell lysates were incubated with anti-
HA affinity gel (Sigma) overnight at 4°C. Immunoprecipitates were washed with 
RIPA buffer three times, and analyzed in Western blot with anti-Flag antibody to 
detect ubiquitin conjugation.  
 
Chromatin immunoprecipitation (ChIP) assay 
Spleens from 2-month old wild-type and Smurf2T/T littermates were harvested 
and processed as described previously to obtain single cell suspension. Splenic 
cells were resuspended in RPMI-1640 medium (Invitrogen) with 1% 
formaldehyde (Sigma) and cross-linking was carried out at room temperature for 
10 minutes. After neutralization with glycine (125 nM), cells were lysed in SDS 
lysis buffer. After sonication, cell extract was used in immunoprecipitation with 
anti-YY1 antibody (sc-281, Santa Cruz Biotechnology) or matched IgG as a 
control. ChIP was carried out using a ChromaFlash one step ChIP kit (Epigentek) 
according to manufacturer’s instruction. After reverse of cross-linking at 65°C for 
3 hrs, amplification of the specific region of c-Myc promoter containing the YY1 
binding site was detected in quantitative PCR with the following primers: F: 5’-
tccccagccttagagagacg-3’ and R: 5’-ggctccggggtgtaaacagt-3’. Chromatin before 
ChIP was used as input for comparison.  
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Cell culture and viral infection 
A human DLBCL cell line SUDHL6 (a generous gift of Dr. Subbarao Bondada, 
University of Kentucky) was cultured in RPMI-1640 medium (Invitrogen) 
supplemented with 10% fetal bovine serum (Hyclone) in a humidified chamber 
containing 5% CO2 at 37°C. Lentiviral vectors expressing Smurf2 or ligase 
mutant C716A were constructed by insertion of Smurf2 cDNA fragments into 
pLenti-CMV-MCS-Puro. Lentiviral shRNA constructs targeting Smurf2 
(V2LHS_10399), YY1 (V2LHS_219592, V2LHS_389741) and a non-silencing 
shRNA control (RHS4346) were purchased from Open Biosystems. These 
Lentiviral shRNA constructs also express GFP. Lentiviral packaging and infection 
were carried out as described previously [284]. Briefly, lentiviral vectors were co-
transfected into 293T cells with a plasmid (pMD2.VSV-G) encoding vesicular 
stomatitis virus glycoprotein (VSV-G) and a plasmid (pCMVdR8.74) encoding 
packaging proteins. VSV-G pseudotyped virus were collected 48 hr after 
transfection and used to infected target cells in the presence of 4 µg/ml 
polybrene (Sigma). Four days later, infected cells were FACS sorted to obtain 
GFP positive (shRNA knockdown) cells or selected with Puromycin (1mg/ml) for 
1 week to obtain Smurf2 or C716A expressing cells. For growth curves, cells that 
were sorted or selected were plated at 5*103 cells/well in 6-well plates in triplicate 
and counted daily for 5 days. 
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Statistical analyses 
Microarray data were retrieved from GEO (http://www.ncbi.nil.nih.gov/geo). 
Expression values of Smurf2 (log2 transformed) were analyzed with Box plot. 
One-way ANOVA was used for statistical analysis. Kaplan-Meier survival curves 
were plotted and analyzed with the log-rank test. Student t-test (two-tailed and 
unpaired) was used for pairwise comparisons, and data were presented as mean 
± standard deviation. Statistical significance was set as P<0.05.  
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CHAPTER IV 
 
 Enhanced Long-term HSC activity in the Smurf2-
deficient mice 
127
ABSTRACT 
 
 
Age-dependent decline in the self-renewal ability of stem cells plays a critical role 
in aging, but the underlying mechanisms of such decline are not well understood. 
Senescence has been hypothesized as one of the mechanisms to contribute to 
the decline of stem cell self-renewal with age, although the evidence to support 
this hypothesis is scant. In this study, we showed that mice deficient in Smurf2, a 
previously identified regulator of senescence, had an expanded hematopoietic 
stem cell (HSC) compartment and this was associated with increased 
proliferation of HSCs. Furthermore, Smurf2-deficient mice exhibited increased 
short-term and long-term self-renewal activity.  Finally, the bone marrow 
compartment of Smurf2-deficient mice exhibit decreased p16INK4a expression 
levels. As decreased expression of p16INK4a, a key senescence regulator, has 
been shown to be associated with decreased hematopoietic stem cell function, 
this provides a plausible mechanism for the phenotype displayed by the Smurf2-
deficient mice. Taken together, these data suggest that Smurf2-deficiency 
regulates HSC activity by delaying senescence through down-regulation of 
p16INK4a.  
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INTRODUCTION 
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Age-dependent decline in stem cell function occurs in several tissues and this 
leads to impairment in tissue homeostasis with age [337,171]. Aging in the 
hematopoietic system is driven by both intrinsic and extrinsic factors 
[154,182,152,337,151] and results in decreased immune response [181], 
increased incidence of myeloid leukemias [338] and anemias [339] and also 
reduced regenerative capacity [340].  
The murine hematopoietic system also exhibits a functional decline with 
age [341,151-153]. In mice, while there is a strain-dependent increase in 
hematopoietic stem cell (HSC) number with age [151-154], it is associated with a 
dose-dependent decrease in self-renewal capacity in serial transplantation 
experiments in vivo [155,156]. This decline in HSC function increases with the 
number of stem cell transplantations [157-161]. HSCs from aged mice also 
exhibit a decrease in competitive repopulating ability compared with younger 
counterparts [162,151,153]. HSCs from mice display a skewing toward the 
myeloid lineage. Mice display changes in lineage potential with age, with a 
decrease in lymphoid output while myeloid potential is maintained [151]. 
While numerous molecular mechanisms have been postulated, the 
pathways that lead to stem cell aging are not well understood. Senescence is 
known to be associated with aging. Thus far, the role of senescence in the 
changes in stem cell functionality with age is debatable. Most of the evidence for 
senescence in stem cell aging comes from studies showing that senescence 
markers such as senescence-associated β-galactosidase, HP-1 
(heterochromatin protein-1) foci, and p16INK4a markedly increase with age in 
130
many tissues in several mammalian species [171] and from studies of self-
renewal in HSCs, from p16INK4a-deficient and p16INK4a-overexpressing mice that 
have suggested that increasing levels of p16INK4a are not only associated with 
aging, but partly contribute to the age-induced replicative failure of HSCs [192].  
Work from our lab has previously shown that Smurf2 is a critical regulator 
of the senescence response [245]. In our Smurf2-deficient mouse-model, we 
observed a delayed senescence response in MEFs as well as in vivo (Chapter 
2). We further showed that this delayed senescence response is associated with 
decreased p16 expression. Work from our lab has also recently shown that 
Smurf2 can regulate p16 expression in a ligase-dependent manner [246], and 
this is integral to Smurf2’s regulation of senescence. Based on Smurf2’s 
regulation of senescence and p16, we hypothesized that Smurf2 regulates HSC 
function in an age-dependent manner in vivo. In this study, we show that Smurf2-
deficiency leads to increased bone marrow and LT-HSC population. Further, 
young and old Smurf2-deficient mice exhibit better self-renewal capacity in a 
serial transplantation experiment in vivo. We also find that the older Smurf2-
deficient HSCs compete better than the young HSCs in a competitive 
repopulation experiment in vivo. This is associated with decreased expression of 
p16 in the bone marrow compartments of the Smurf2-deficient mice. Our data 
thus indicate that Smurf2 may regulate LT-HSC function by regulating the 
senescence response through the downregulation of p16 expression. 
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RESULTS 
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Smurf2-deficiency leads to an expansion of the bone marrow compartment 
and the LT-HSC population 
We focused our initial analysis on the whole bone marrow of Smurf2-deficient 
mice. BM counts from littermates of wild-type and Smurf2-deficient mice showed 
an expansion of the BM compartment in the young Smurf2-deficient mice 
(Fig.4.1a) which was maintained as the mice aged (Fig.4.1b). We then extended 
our study to the BM LT-HSC compartment (Lin- Sca+ c-kit+ CD135- CD150+) in 
littermates from wild-type and Smurf2-deficient mice, and found that the Smurf2-
deficient mice showed an expansion of the LT-HSC compartment (Fig.4.1c). The 
Smurf2-deficient mice exhibited a sustained increase in the frequency as well as 
the absolute number of LT-HSCs in the BM of young (Fig4.1d) as well as old 
(Fig.4.1e) mice.  
To investigate if the increase in LT-HSC count also led to an increase in 
the other hematopoietic progenitors, we studied the other stem cell and 
progenitor compartments in the BM. When we examined the other HSC 
compartments from wild-type and Smurf2-deficient mice, we found no difference 
in the less immature progenitor compartments including the Lineage depleted BM 
cells (Lin-) (Fig.4.2a), the LSK population (Lin- Sca+ c-kit+) (Fig.4.2b), the Short-
term HSCs (ST-HSCs: Lin- Sca+ c-kit+, CD135- CD150-) (Fig.4.2c) or the Multi-
potent progenitors (MPPs: Lin- Sca+ c-kit+, CD135+ CD150-) (Fig.4.2d). This 
indicates that there is a specific increase in the frequency of the LT-HSCs in the 
Smurf2-deficient mice.  
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 To determine if the effector cells in circulation that arise from the HSCs in the 
BM are changed by Smurf2-deficiency, we performed complete blood counts on 
peripheral blood from age-matched wild-type and Smurf2-deficient mice. There 
was no difference in the various blood cell lineages including WBCs, 
Lymphocytes, Granulocytes and Monocytes (Fig.4.3) between wild-type and 
Smurf2-deficient mice. Thus, the increased LT-HSC number has no effect on the 
resting population of blood cells in circulation.  
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Fig.4.1: Increased total bone marrow counts in young and  aged Smurf2T/T 
mice. (a)Total bone marrow counts from littermates of 2-month old wild-type 
(+/+) and Smurf2-deficient (Smurf2T/T) (T/T) mice (n=16) are shown. p=0.0121  
(b) Increased bone marrow counts in aged Smurf2T/T mice. Total bone marrow 
counts from littermates of 24-month old wild-type (+/+) and Smurf2-deficient 
(Smurf2T/T) (T/T) mice (n=4) are shown. p=0.007, Paired Student’s t-test (2-
tailed) was used for statistical analysis. Statistic significance is indicated as: * 
(P<0.05), ** (P<0.01), and *** (P<0.001). 
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Fig.4.1 
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Fig.4.1c: Expanded LT-HSC population in the Hematopoietic stem cell 
compartment of Smurf2T/T mice. FACS analyses of BM cells stained with the 
HSC cocktail from wild-type (+/+) (upper panel) and Smurf2T/T (T/T) (lower panel) 
littermates are presented. Live cells are displayed (propidium iodide excluding). 
LT-HSCs are Lin-, Sca+, c-kit+, CD135-, CD150+. Lineage (Lin) negative cells 
(left panel) are gated out and Sca1 and c-kit staining on this population is 
displayed in the middle panel. The Sca+, c-kit+ cells are defined as the LSK (Lin-
, sca+, c-kit+) population. LSK cells are further gated out (middle panel) and 
stained for CD135 and CD150 (right panel). LT-HSCs are CD135-, and CD150+, 
as displayed in the right panel. ST-HSCs are CD135-, and CD150- and are 
displayed in the box left of the LT-HSCs. MPPs are CD135+, CD150- and are 
displayed in the right panel. The Smurf2T/T (T/T) mice exhibit an expanded LT-
HSC compartment (16% to 9%).  
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Fig.4.1c 
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Fig.4.1(contd): Expanded LT-HSC compartment in the bone marrow of 
Smurf2T/T mice. LT-HSCs are Lin-, Sca+, c-kit+, CD135-, CD150+ as determined 
by FACS analysis. The frequency and absolute numbers of LT-HSCs in the total 
BM of young (d) 2-month old (upper panel, n=10, p=0.03) mice and aged (e) 24-
month old (lower panel, n=4, p=0.02) wild-type (+/+) and Smurf2T/T (T/T) are 
displayed. Paired Student’s t-test (2-tailed) was used for statistical analysis.  
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Fig.4.1 
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Fig.4.2: The other stem and progenitor cell compartments are unchanged in 
the BM of Smurf2T/T mice. Cells that stain negative for the Lineage cocktail are 
called Lin-; the LSK population is defined as Lin-, Sca+, c-kit+; ST-HSCs are 
LSK, CD135-, and CD150-; MPPs are LSK, CD135+, CD150- as determined by 
FACS analysis. The frequency of Lin- cells (a), LSK cells (b), ST-HSCs (c) and 
MPPs (d) in the total BM of young 2-month old (n=10) wild-type (+/+) and 
Smurf2T/T (T/T) are displayed and there is no apparent difference between them.  
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Fig.4.2 
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Fig.4.3: Peripheral blood counts in the Smurf2T/T mice are unchanged. 
Complete blood counts on peripheral blood from 2 month old WT (+/+) and 
Smurf2T/T (T/T) littermates (n=6) are displayed. The White Blood Cell (WBC) 
count, Lymphocyte count, Monocyte count and Granulocyte count are similar 
between the WT (+/+) and Smurf2T/T (T/T) mice.  
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Fig.4.3 
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Smurf2-deficient LT-HSCs exhibit better self-renewal capacity in vivo 
To evaluate the functional capacity of the Smurf2-deficient LT-HSCs we 
performed a serial transplantation experiment. As a gold standard test for long-
term self-renewal and multi-lineage potential of HSCs, serial transplantation of 
bone marrow cells is able to reconstitute lethally-irradiated recipients in 
successive but limited transplants, reflecting the finite potential of HSC self-
renewal [159,161,342]. It has been shown that serial transplantation leads to a 
dose-dependent decrease in self-renewal capacity of HSCs [155,156].  
Total BM cells (5*106) from young wild-type or Smurf2-deficient mice were 
injected into lethally irradiated (10Gy) recipients. In order to distinguish the 
relative contributions of the donors from the recipients we used recipient mice of 
a congenic strain bearing the allelic variant CD45.1 that can be distinguished 
from the donors (CD45.2) by flow cytometric analysis. We were able to rescue 
100% of the recipients from wild-type and Smurf2-deficient mice for the first 3 
cycles of transplantations (Fig.4.4a). In the 4th cycle, 100% of the recipients of 
wild-type BM died within 3 weeks of being transplanted, but up to 70% of the 
recipients of Smurf2-deficient BM survived (Fig.4.4a). When we carried recipients 
of the Smurf2-deficient BM forward for the 5th transplantation, 60% of the injected 
mice survived (Fig.4.4a). Further, staining of the BM from the recipient mice with 
the CD45.2 anitbody in conjunction with the HSC cocktail 2 months after 
transplantation revealed that ˜ 95% of the LT-HSC population had been 
reconstituted by the donor BM (Fig.4.4b) with almost no residual recipient HSCs 
surviving irradiation. To determine if the newly reconstituted HSCs in the bone 
145
marrows of the recipient mice were able to form the various blood cell lineages, 
we bled the mice and performed CBC counts at 2 months after reconstitution. We 
found that both wild-type and Smurf2-deficient HSCs were able to successfully 
reconstitute all the blood cell lineages (Fig.4.4c). These data indicate that the 
young Smurf2-deficient LT-HSCs may have better self-renewal capacity in vivo, 
allowing them to reconstitute bone marrow for more number of transplantation 
cycles than wild-type. When we examined the bone marrows of the recipients 
from successive transplantations we found that the increase in total BM count 
and LT-HSC count was maintained by the recipients of the Smurf2-deficient BM 
(Fig.4.4d). This indicates that the better functional capacity of the Smurf2-
deficient LT-HSCs is likely a cell-intrinsic phenomenon and independent of the 
microenvironment.   
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Fig.4.4a: Smurf2T/T (T/T) deficient mice exhibit increased self-renewal 
capacity in vivo. Kaplan-Meier curves from the serial transplantation experiment 
showing survival of recipients of wild-type (+/+) and Smurf2T/T (T/T) BM over 
successive transplants are displayed. 5*106 BM cells from a healthy 2 month-old 
WT (+/+) and Smurf2T/T (T/T) donor CD45.2+ mice are injected into lethally 
irradiated (10Gy) CD45.1+ recipient mice (n=5) for the 1st 3 transplantations. The 
experiment was repeated twice (upper panel 1st set, lower panel 2nd repeat). For 
the 4th transplantation, BMs from 3° transplant recipients (n=22 for the 1st set 
p<0.0001, n=8 for the 2nd repeat p< 0.0004) were injected. Recipients of 
Smurf2T/T (T/T) BM were able to reconstitute mice for up to 5 transplants, 
compared to 3 for wild-type. For the 1st set, the 4th transplant T/T survivors were 
carried forward for the 5th transplant. Curve comparison was performed using the 
log-rank test.  
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Fig.4.4a 
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Fig.4.4b: HSCs in the transplant recipients are derived from donor bone 
marrow. FACS analyses of BM cells stained with the CD45.2+ antibody along 
with the HSC cocktail from wild-type (+/+) (upper panel) and Smurf2T/T (T/T) 
(lower panel) littermates are presented. Live cells are displayed (propidium iodide 
excluding). Lin- cells are gated out (left panel) and stained for CD45.2 (middle left 
panel). The CD45.2+ (donor) cells are gated (middle left panel) and then further 
stained for Sca1 and c-kit (middle right panel). The LSK population (Lin- Sca+ c-
kit+) cells are gated (middle right panel) and stained for CD135 and CD150 (right 
panel) to determine the LT-HSC population (Lin-, Sca+, c-kit+, CD135-, 
CD150+).  
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Fig.4.4b 
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Fig.4.4c: HSCs from reconstituted transplant recipients can form all the 
blood cell lineages effectively. Recipients of each transplantation from both 
wild-type (+/+) and Smurf2T/T (T/T) mice (n=3) were bled 4 months after 
transplantation and complete blood counts were performed. Recipients of both 
wild-type (+/+) and Smurf2T/T (T/T) BM were able to form WBCs, Lymphocytes, 
Granulocytes and Monocytes effectively. 
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Fig.4.4c 
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Fig.4.4d: Recipients of Smurf2T/T (T/T) BM display increased total BM and 
LT-HSC number in the serial transplantation experiment. BM counts from 
recipients of successive transplants from wild-type (+/+) (open bars) and 
Smurf2T/T (T/T) (black bars) donors (left panels) are shown. LT-HSC counts from 
the same animals as determined by FACS analysis are displayed in the right 
panels. Upper panel is the 1st set of transplantations. Lower panel is the 2nd 
repeat. Since WT (+/+) recipients were not available after the 3rd transplantation, 
a 3rd transplant WT (+/+) recipient was sacrificed as a control for the 4th and 5th 
transplantation experiments. In each case, the Smurf2T/T (T/T) mice exhibited 
increased total BM and LT-HSC populations compared to WT (+/+).  
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Fig.4.4d 
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Aged Smurf2-deficient LT-HSCs exhibit better self-renewal capacity in vivo 
To investigate if the old Smurf2-deficient LT-HSCs also exhibited better self-
renewal capacity compared to their wild-type counterparts we performed serial 
transplantation experiments using 24-month old wild-type and Smurf2-deficient 
littermates as donors. The old Smurf2-deficient mice were able to carry forward 
the transplantations to the 4th cycle with 100% of the recipients surviving the 4th 
transplant, while the recipients of wild-type marrow died within 20 days of the 4th 
transplantation (Fig.4.5a). CBC counts from the bloods of the reconstituted 
recipients revealed that the HSCs from both wild-type and Smurf2-deficient mice 
were able to effectively form the various blood cell lineages (Fig.4.5b). Similar to 
the recipients of young Smurf2-deficient marrow, the old recipients also 
maintained the increase in total BM count as well as LT-HSC numbers over 
successive transplants (Fig.4.5c). Thus, the increased self-renewal capacity of 
the Smurf2-deficient mice was sustained as the mice aged. This indicates that 
the increased self-renewal capacity of the young Smurf2-deficient LT-HSCs did 
not lead these mice to exhaust sooner.  
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Fig.4.5a: Aged Smurf2T/T (T/T) deficient mice exhibit increased self-renewal 
capacity in vivo. Kaplan-Meier curves from the serial transplantation experiment 
showing survival of recipients of wild-type (+/+) and Smurf2T/T (T/T) BM over 
successive transplants are displayed. 5*106 BM cells from a healthy 24 month-
old WT (+/+) and Smurf2T/T (T/T) donor mice (mixed background) are injected 
into lethally irradiated (10Gy) recipient mice (mixed BL/6:129/Sv, n=5) for the 1st 
3 transplantations. For the 4th transplantation, BMs from 3° transplant recipients 
were injected into 10 recipient mice each. Recipients of Smurf2T/T (T/T) BM were 
able to reconstitute mice over 4 transplants, compared to 3 for wild-type, 
p<0.0001. Curve comparison was performed using the log-rank test.  
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Fig.4.5a 
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Fig.4.5b: HSCs from reconstituted transplant recipients can reconstitute all 
the blood cell lineages effectively. Recipients of each transplantation from 
aged wild-type (+/+) and Smurf2T/T (T/T) (n=3) mice were bled 4 months after 
transplantation and complete blood counts were performed. Recipients of both 
aged wild-type (+/+) and Smurf2T/T (T/T) BM were able to form WBCs, 
Lymphocytes, Granulocytes and Monocytes effectively and with no apparent 
difference.  
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Fig.4.5b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
159
Fig.4.5c: Recipients of aged Smurf2T/T (T/T) BM display increased total BM 
and LT-HSC number in the serial transplantation experiment. BM counts 
from recipients of successive transplants from aged wild-type (+/+) (black bars) 
and Smurf2T/T (T/T) (grey bars) donors (upper panel) are shown. LT-HSC counts 
from the same animals as determined by FACS analysis are displayed in the 
lower panels. The recipients of Smurf2T/T  BM display a consistent increase in the 
total BM and LT-HSC count over several transplantations compared with wild-
type.  
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Fig.4.5c 
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Old Smurf2-deficient LT-HSCs compete more robustly than wild-type in a 
Competitive Repopulation Assay 
To test the ability of the Smurf2-deficient LT-HSCs to repopulate the BM of stem-
cell depleted mice relative to wild-type LT-HSCs, we performed a competitive 
repopulation experiment. In this experiment we injected either wild-type or 
Smurf2-deficient (both CD45.2) BM mixed in a 1:1 ratio with competitor BM 
(CD45.1/2) into lethally irradiated CD45.1 recipient mice. We performed this 
experiment using young (2 month old) or old (24 month old) donors and 
competitors of corresponding ages. We assayed for B-cells, T-cells and Myeloid 
cells in the blood of the recipient mice every month, starting 2 months after 
transplantation. To determine the relative contribution of the donor HSCs to the 
reconstituted cells we calculated the Repopulating Unit (RU) of the donor 
towards each lineage of cells. The RUs from young wild-type and Smurf2-
deficient LT-HSCs were similar (Fig.4.6) in all the 3 lineages we tested. However, 
the old Smurf2-deficient LT-HSCs exhibited at least ~2-fold better RU activity 
than their wild-type counterparts (Fig.4.6). These data suggest that the LT-HSCs 
from aged Smurf2-deficient mice have better short-term repopulating activity than 
wild-type LT-HSCs.  
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Fig.4.6: Aged Smurf2T/T LT-HSCs display better short-term repopulating 
ability than wild-type. The competitive repopulation experiment was performed 
using young (2-month old) and aged (24 month old) wild-type (+/+) and Smurf2T/T 
(T/T) donors with BM from a young CD45.1/2 as a competitor. Recipient mice 
(n=5) were bled monthly and FACS analysis was performed to determine the 
percentage of B220+, CD3+ and CD11b+ cells along with CD45.1+ and CD45.2+ 
cells to estimate the relative contributions from donor and competitive BMs. RUs 
for each lineage (B-cell, T-cell and Myeloid) are shown for recipients of both 
genotypes on the Y-axis. The upper panel shows the RUs at 2 months and the 
lower panel for 3 months after transplantation. Recipients of young BM showed 
no difference between the wild-type and Smurf2T/T donors. But the recipients of 
BM from aged wild-type and Smurf2T/T BM showed a significant increase in the 
RUs for all 3 lineages tested. Paired Student’s t-test (2-tailed) was used for 
statistical analysis. Statistic significance is indicated as: * (P<0.05), ** (P<0.01), 
and *** (P<0.001). 
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Fig.4.6 
 
164
Smurf2-deficient HSCs exhibit increased proliferation and decreased 
quiescence and this is associated with decreased p16 expression. 
In addition to the enhanced competitive repopulation ability of the aged Smurf2-
deficient LT-HSCs (Fig.4.6), the young and old Smurf2-deficient LT-HSCs also 
have better self-renewal capacity (Figs.4.4 and 4.5). This led us to investigate the 
cell-cycle profiles of Smurf2-deficient HSCs to test if they proliferate better than 
wild-type. We stained the LSK, CD135- BM cells from both genotypes for Ki67 
and DAPI. The Smurf2-deficient LT-HSCs exhibited increased numbers (1.5% in 
wild-type to 6% in Smurf2-deficient) of cells in the S-phase and decreased 
numbers of cells in the G1 phase (Fig.4.7a). We further labeled the wild-type and 
Smurf2-deficient mice with BrdU and found that the Smurf2-deficient LSK, 
CD150+ cells exhibited increased proliferation compared with wild-type 
(Fig.4.7b).  
 p16INK4a deficiency in the HSC compartment attenuated the age-induced 
decline in proliferation and function [192], which was a phenotype that we also 
found  in the Smurf2-deficient LT-HSCs in this study. Since the spleens and 
MEFs from Smurf2-deficient mice have been shown to exhibit decreased p16INK4a 
expression, we investigated whether the BM from these mice also behaved 
similarly. Aged Smurf2-deficient BM exhibited lower p16INK4a expression 
compared to wild-type by quantitative Real-time PCR (Fig.4.8a). When we 
compared p16INK4a  expression within the recipients of aged wild-type and 
Smurf2-deficient BM from different stages of the serial transplantation 
experiment, we found that the Smurf2-deficient BMs exhibited attentuated 
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kinetics of p16INK4a upregulation compared with wild-type (Fig.4.8b). This 
suggests that the lower levels of p16INK4a expression in the BM of the Smurf2-
deficient mice might be responsible for a delayed senescence phenotype within 
the LT-HSC compartments of these mice. This could potentially be responsible 
for the increased proliferation phenotype exhibited by the Smurf2-deficient LT-
HSCs.  
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Fig.4.7: Smurf2T/T HSCs display increased proliferation and decreased 
quiescence. (a) BMs from WT (+/+) and Smurf2T/T LT-HSCs (T/T) were stained 
for the HSC cocktail and then fixed and stained for Ki-67 and DAPI. The left 
panel represents a FACS analysis plot of WT (+/+) LSK, CD135- cells that are 
stained for DAPI and Ki-67. A similar panel for the Smurf2T/T LSK, CD135- cells is 
shown in the right panel. The Smurf2T/T HSCs exhibit increased percentage of 
cells in the S-phase (6% in T/T to 1% in +/+) and decreased percentage of cells 
in the G0 phase. (b) WT (+/+) and Smurf2T/T mice were injected with BrdU and 
sacrificed 24 hours later. BMs from WT (+/+) and Smurf2T/T LT-HSCs (T/T) were 
stained for the HSC cocktail and then fixed and stained for BrdU. The left panel 
represents a FACS analysis plot of WT (+/+) LSK, CD150+ cells that are stained 
for BrdU. ). A similar panel for the Smurf2T/T LSK, CD150+ cells is shown in the 
right panel. The Smurf2T/T HSCs exhibit increased BrdU incorporation (68% to 
36% in the WT).  
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Fig.4.7      
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Fig.4.8: Aged Smurf2T/T BM have lower p16INK4a expression levels. (a) 
p16INK4a  expression in the BM of 18-month old WT (+/+) and Smurf2T/T (T/T) mice 
was analyzed by quantitative RT-PCR. (b) p16INK4a  expression in the BM of  
recipients of WT (+/+) (1st transplantation) and Smurf2T/T (T/T) (4th 
transplantation) BM was analyzed by quantitative RT-PCR. Relative expression 
in wild-type BM cells was set to be 1 after normalization with β-actin. Error bars 
were calculated from standard deviations of three independent experiments.  
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Fig.4.8 
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DISCUSSION 
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In this study we have shown that the Smurf2-deficient mice have increased BM 
and LT-HSC numbers. This is further associated with increased self-renewal 
activity of young and old Smurf2-deficient mice in a serial transplantation 
experiment. Further, only the old (but not the young) Smurf2-deficient mice 
displayed better reconstitutive capability in a competitive repopulation assay, 
indicating that the aged Smurf2-deficient LT-HSCs have better short-term 
repopulating activity than wild-type LT-HSCs. Further, cell cycle analysis of the 
HSCs determined that the Smurf2-deficient LT-HSCs were less quiescent and 
tended to proliferate more than wild-type. In addition, p16INK4a expression was 
lower in aged Smurf2-deficient BM than wild-type. Also, the kinetics of p16INK4a 
upregulation were attenuated in the recipients of Smurf2-deficient BM in the 
serial transplantation experiment at different cycles of transplantation. We have 
previously shown that spleens from the Smurf2-deficient mice exhibit increased 
proliferative capacity and this is associated with delayed senescence and 
decreased p16INK4a expression. Our data further show that the aged Smurf2-
deficient mice partially mimic the p16INK4a  knockout mice, behaving like the aged 
p16INK4a knockout mice in the competitive repopulation assay [192]. Work from 
our lab has shown that Smurf2 regulates p16INK4a  by ubiquitinating ID1 [246]. ID1 
expression is known to be enriched in the HSC compartment in mice [343]. It 
would be interesting to look at ID1 expression in the LT-HSCs of Smurf2-deficient 
mice, to test if it is increased compared to the WT-LT-HSCs, thereby providing a 
plausible molecular mechanism for Smurf2-mediated regulation of p16INK4a 
activity in the LT-HSC compartment.  
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Activation of the senescence response has not been well described in stem cell 
compartments. This is partially due to the fact that most stem cell compartments 
exhibit high levels of telomerase expression, thereby lessening the burden of 
telomere shortening on these cells. However, telomere shortening has been 
demonstrated in murine HSCs [344] during serial transplantation. Further, the 
phenotypes of the mTERC−/− mice indicate that telomere shortening plays an 
important role in regulating stem cell function. Since Smurf2 is known to be a 
critical regulator of senescence in response to telomere shortening, we 
hypothesize that a delayed senescence response in the Smurf2-deficient LT-
HSCs, which is associated with the downregulation of p16INK4a in these cells, 
maybe responsible for the ability of these cells to proliferate better without 
undergoing stem-cell exhaustion. More work is necessary to ascertain if the 
senescence response is indeed delayed in the Smurf2-deficient LT-HSCs and if 
this phenotype is in fact, ID1 dependent.  
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MATERIALS AND METHODS: 
Flow Cytometry 
Mice were euthanized with isoflurane and cervical dislocation. Bone marrow was 
harvested from all 4 limbs of the mice using the femurs, tibiae and humerii. Cells 
were counted using a hemocytometer. The cells were then resuspended at 
6x107/ml in staining medium which consists of Biotin-, flavin and phenol red-
deficient RPMI-1640 medium (Invitrogen) supplemented with 10 mM HEPES (pH 
7.2), 1 mM EDTA, 2% FBS and 0.02% sodium azide. Bone marrow cells were 
filtered through 70 µm nylon mesh and incubated with anti-CD16/32 antibody 
(Bio X Cell) for 10 min on ice to block Fc receptors. Cells were incubated with 
primary antibodies for 20 min and washed three times. All antibiodies are from e-
Bioscience unless otherwise specified. The antibodies used include the Lineage 
cocktail that contains biotin-conjugated Ter119 (clone TER-119), CD11b (clone 
M1/70), Ly-6G (Gr1, clone RB6-8C5), CD45R (B220, clone RA3-6B2), CD19 
(clone 1D3) and CD3e (clone 145-2C11). Additional antibodies for HSC analysis 
include Ly-6A/E (Sca1)-FITC (clone D7), CD117 (c-Kit)-PE-Cy7 (clone 2B8), 
CD135 (Flt3)-PE (clone A2F10) and CD150-APC (clone mShad150). Cells 
stained with biotin-labeled antibodies (lineage cocktail) are incubated with 
streptavidin-eFluor 450 for 15 min on ice and washed three times with staining 
medium. After the final wash, cells are resuspended in 1 µg/ml propidium iodide 
(PI) in staining medium for the exclusion of dead cells. Flow cytometry analysis is 
performed on a 5-laser, 18-detector LSR II FACS machine using 405, 488, 561 
and 633-nm lasers. Data are analyzed using FlowJo software (Treestar).  
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Complete Blood Counts 
Tail veins of mice were bled into EDTA coated tubes and complete blood counts 
were performed using the Heska CBC-Diff Veterinary Hematology System 
(Heska).  
 
Serial transplantation and Competitive Repopulation:  
Young (2 mo old) and Old (24 mo old) WT and Smurf2-deficient mice were used 
as donors for these experiments. B6.SJL-Ptprca Pepcb/BoyJ (CD45.1+) aged 8-
10 weeks (The Jackson Laboratory) were used as recipients. CD45.1+/- mice 
were used as the competitors for the competitive repopulation experiment. 
Recipient mice are treated with antibiotics in drinking water 24 hours prior to 
exposure to radiation. Recipient mice are exposed to a lethal dose of 10 grays 
(1000 Rads) whole body radiation using a Cesium-137 source. At least 5 
recipient mice were used for each donor. For later (>3) cycles of transplantation, 
at least 10 recipient mice were used per donor. 5x106 bone marrow cells (~200 
HSCs) per recipient mouse were injected retro-orbitally into the recipient mice. 
Anti-mouse CD45.2 FITC (Clone 104) and Anti-mouse CD45.1 Pe-Cy7 (Clone 
A20) were used to analyze the relative contributions from the donors and 
recipients in the bloods and bone marrows from the reconstituted recipients.  
For the competitive repopulation experiment, Repopulating Units were calculated 
using the formula RU(D) = RU(C)     %D           where RU(C) was set as 20 [345].  
                                                  100-%D    
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RU(C) was defined as 1 per 105 competitor cells where C stands for competitor 
and D for donor) 
 
Cell Cycle Analysis:  
Mice were injected intra-peritoneally with 1mg BrdU per mouse every 6 hours for 
24 hours as described previously[346]. Bone marrow cells were stained for the 
LT-HSCs as described above, and fixed and permeabilized using the BrdU Flow 
kit (BD Biosciences) and stained for FITC-BrdU or PerCp-Cy5.5-ki-67 (Clone 
Sola15) for 20 minutes. Ki67 stained cells were further incubated with DAPI for 
30 minutes at room temperature as described previously [347].  
Quantitative PCR 
Total RNA was isolated from freshly dissected tissues using Trizol (Invitrogen). 
RNA was reverse-transcribed using Superscript II (invitrogen). Real-time PCR 
was carried out on a MyiQ iCycler using a SYBR Green PCR kit (Bio-Rad). The 
following primers were used: β-actin (F: 5’-GCTCTTTTCCAGCCTTCCTT-3’, R: 
5’-GTGCTAGGAGCCAGAGCAGT-3’) and p16 (5’-CGAACTCTTTCGGTCG-
TACCC-3’ and 5’-CGAATCTGCACCGTAGTTGAG-3’).  
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CHAPTER V 
SUMMARY & CONCLUSIONS 
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  Cellular senescence has been postulated to function in an antagonistically 
pleiotropic manner, by preventing malignant transformation in young mammals 
but promoting aging over a lifespan, thus providing support for the Antagonistic 
Pleiotropy Theory of aging. Several studies have provided evidence strongly 
supporting the tumor suppressor function of senescence [77,83], however, the 
evidence supporting senescence’s role in aging is as yet inconclusive. In this 
thesis I attempted to test the Antagonistic Pleiotropy Theory of senescence and 
aging. I manipulated the senescence response in vivo, by manipulating the 
expression of a key senescence regulator, Smurf2 and tested the effects of such 
manipulation on cancer and aging.  
In Chapter II I described the generation of a Smurf2-deficient mouse 
model that exhibited an increased susceptibility to spontaneous tumorigenesis, 
indicating that Smurf2 has a tumor suppression function. Increased 
tumorigenesis was preceded by an impaired senescence response and 
associated with decreased p16 expression in pre-malignant spleens and primary 
fibroblasts of Smurf2-deficient mice. In Chapter III I characterized the lymphomas 
from the Smurf2-deficient mice as GCB-type DLBCL. Further, we showed that 
Smurf2 is the E3 ligase for YY1, a transcription factor known to activate c-Myc 
that is postulated to play a role in GC development [330]. These findings suggest 
that Smurf2’s tumor suppressor function is not merely restricted to its regulation 
of the senescence response, but is also associated with its function as an E3 
ligase. Smurf2-mediated ubiquitination of YY1, leading to the activation of c-Myc 
is one such important regulatory axis in lymphomagenesis. The Smurf2-deficient 
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mice also develop other kinds of tumors, including hepatocellular carcinoma, 
intestinal adenocarcinoma and sarcomas. There could be other potential targets 
of Smurf2-mediated ubiquitination that may play an important role in the 
development of these tumors, or they could arise as a consequence of the 
delayed senescence in the Smurf2-deficient mice.  
The fact that Smurf2 regulates tumor suppression through multiple 
mechanisms adds a layer of complexity to our hypothesis that Smurf2 functions 
as an antagonistic pleiotropic trait by regulating senescence. Since we do not 
know which mechanism is more critical to Smurf2’s function in tumor 
suppression, it would be interesting to devise ways to uncouple the 2 functions of 
Smurf2 in regulating senescence, and as an E3 ligase, and test if the functions 
on tumor suppression in vivo are different.  
 We have also found that low Smurf2 expression is associated with poor 
prognosis in patients with DLBCL. This correlates with a previous observation 
that high levels of YY1 expression correlate with poor survival prognosis in 
DLBCL patients [328] and suggests that the Smurf2-YY1 regulatory axis is a 
useful predictor of clinical outcome in DLBCL patients and a potential therapeutic 
target for treatment of DLBCL. Current therapies for DLBCL are not adequate, 
and 50% patients do relapse even after therapy [348]. While R-CHOP is more 
specific than CHOP therapy in that it targets B-cells, more targeted therapy is 
essential to ensure complete cure. Drugs that specifically target the GC B-cell 
are essential to the treatment of GCB-type DLBCL. We believe that the Smurf2-
YY1 axis might provide an important therapeutic target in developing more 
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specific therapy for GCB-type DLBCL. Further, our finding that Smurf2 regulates 
c-Myc in GCB type DLBCL also has therapeutic value. Thus far, c-Myc has only 
been known to play a role in Burkitt’s Lymphoma, but not the other types of 
DLBCL. We now provide evidence that c-Myc can also be targeted in other types 
of DLBCL.  
After confirming that Smurf2 functions as a tumor suppressor in vivo, we 
chose to investigate the role of Smurf2 in aging in Chapter IV. We found that the 
Smurf2-deficient mice have enhanced LT-HSC activity, and proliferate better 
than wild-type HSCs. Furthermore, we found that the aged Smurf2-deficient LT-
HSCs also exhibit better competitive ability in vivo, and this enhanced activity 
was associated with lower p16 expression in aged Smurf2-deficient BM. The 
activation of senescence in stem cell compartments is not well described. Our 
findings suggest that Smurf2-deficiency might potentially regulate the 
senescence response in the LT-HSC compartment through its regulation of p16. 
However, more work is necessary to conclusively determine Smurf2’s function in 
aging.  
In this thesis, I have described two opposing functions of Smurf2: as a 
tumor suppressor in young mice, and a negative regulator of HSC activity in aged 
mice. These paradoxical functions of Smurf2 suggest that by regulating the 
senescence response, Smurf2 functions as an antagonistic pleiotropic trait in 
vivo. Further, we have shown that Smurf2 regulates the senescence response 
through its regulation of p16.  
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p16  is an important regulator of senescence that is transcribed from the 
INK4a/ARF locus, along with ARF. p16 expression has been shown to increase 
with increasing passage number of cells in culture. In the case of MEFs, 
senescence in culture occurs despite their having long telomeres and high levels 
of telomerase, but this telomere-independent clock is attenuated in cells 
genetically deficient in the INK4a/ARF locus [349]. Further, the p16 null mice 
have been shown to be tumor prone [80]. Activation of an oncogene such as Ras 
leads to the activation of a tumor-protective senescence response called 
oncogene-induced senescence through the upregulation of p16 [350]. The 
expression of p16 is known to increase in rodent and human tissues with age 
[351,352], suggesting that is an important regulator of aging. The age-induced 
expression of p16INK4a in adult stem cells has been shown to be associated 
with impaired tissue regeneration of the pancreatic islets, hematopoietic system, 
and neuronal progenitors [192-194]. Complementarily, the p16 deficient mice 
exhibit increased regeneration potential [194,192,193]. High levels of p16 have 
been postulated to result in p16-induced senescence of the stem cells.  Taken 
together, these data suggest that p16 may function as an antagonistic pleiotropic 
trait through its regulation of the senescence response in vivo. Our findings that 
Smurf2 functions antagonistically by regulating the senescence response through 
its regulation of p16, are supported by the findings that p16 functions as an 
antagonistic pleiotropic trait itself.  
In vivo data in mammalian model systems to support the antagonistic 
pleiotropy theory of senescence and aging is still meager. Apart from p16 and 
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p53 [353], there are few examples of genes that function as senescence 
regulating antagonistic pleiotropic traits. A general problem in the field is that the 
role of senescence in aging has not been conclusively proven. Recent criticism of 
the antagonistic pleiotropy theory of senescence and aging suggests that the 
beneficial and detrimental effects of senescence might occur at any age [354]. 
For example, senescence might function as a tumor suppressor mechanism 
even in the old, while leading to aging phenotypes in the young, and it has been 
shown that senescent cells, once formed tend to stay in the organism for years 
[105,355]. However, a recent study has shown that when senescent cells marked 
by p16 are cleared from a progeroid mouse model, some of the aging 
phenotypes are delayed [356]. It might be interesting to speculate that with the 
help of this model as a tool, the temporal clearance of senescent cells might help 
to dissect the beneficial (tumor suppressive) and detrimental (acceleration of 
aging phenotypes) effects of senescence at different ages. This would help to 
conclusively prove the role of senescence as an antagonistic pleiotropic trait.  
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FUTURE DIRECTIONS 
 
The function of Smurf2 in aging needs to be explored more thoroughly in order to 
determine that Smurf2 truly functions as an antagonistic pleiotropic trait. It would 
be interesting to look at other stem cell compartments in the Smurf2-deficient 
mice to test if their function is as enhanced as the HSC compartment of these 
mice. The generation of transgenic mice that overexpress either wild-type or the 
C716A ligase-dead Smurf2 can help in furthering our understanding of Smurf2’s 
function in senescence and aging. If increased Smurf2 expression truly functions 
to enhance the aging process, we might speculate that these mice will exhibit 
shorter life-span than wild-type and also have other aging-associated 
phenotypes. It will be crucial to test the LT-HSC activity in these mice as well, to 
see if it is abrogated, compared to wild-type. Further the comparison between the 
mice that overexpress wild-type versus the C176A mutant Smurf2 will be 
interesting. Since we have already shown that Smurf2’s role as a tumor 
suppressor also involves its E3 ligase function, I believe this comparison will 
provide some interesting differences that might enable us to tease out the 
different functions of Smurf2 in various processes.  
Further, since we have shown that Smurf2 regulates p16 by targeting ID1 
for ubiquitin-mediated degradation [246], the generation of the Smurf2, ID1 
double knock-out mouse model would also be a powerful tool to test if the 
Smurf2-p16 axis is truly responsible for the senescence-regulated phenotypes 
displayed by the Smurf2 knockout mouse.  
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It would be interesting to investigate other targets of Smurf2-mediated 
ubiquitination and study their function in tumorigenesis. One method to identify 
new targets is to annotate all proteins that contain a PPXY motif, and have the 
potential to interact with Smurf2’s WW domain. A thorough literature review will 
then identify genes from this list that play a role in tumorigenesis and are 
potentially important for Smurf2’s function in tumor suppression, and are thus, of 
interest to us.  
I have shown in Chapter 3, that Smurf2 regulates YY1 and this might be 
responsible for the lymphomagenesis in the Smurf2-deficient mice. In order to 
further confirm that Smurf2 regulates YY1, it is essential that the interaction 
between Smurf2 and YY-1 be demonstrated endogenously. Further, in order to 
conclusively show that Smurf2 is the E3 ligase that ubiquitinates YY1 under 
physiological conditions, the in vivo ubiquitination assay must be performed using 
endogenously expressed YY1 and Smurf2.  
I have shown that Smurf2 regulates lymphoma cell proliferation through its 
regulation of YY1 in a GCB lymphoma cell line.  While the role of Smurf2 in 
regulating lymphoma cell proliferation has been adequately demonstrated by 
both the overexpression and knockdown experiments, YY1 was shown to be 
necessary for Smurf2’s effect on cell proliferation in the double knockdown 
experiment where both Smurf2 and YY1 were simultaneously knocked down 
using shRNA. In order to show that YY1 is sufficient for Smurf2’s effect on cell 
proliferation, YY1 must be overexpressed in the cell line to see if it increases cell 
proliferation, akin to Smurf2 knockdown. Further, it will be interesting to test if in 
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the double overexpression experiment, the increased YY1 expression can 
partially or completely abrogate Smurf2’s effect on cell proliferation. I have 
previously tried to overexpress YY1 in the SuDHL6 cell line and found that the 
cells underwent apoptosis. This is not completely unexpected, since we as well 
as others have shown that YY1 transactivates c-Myc. Increased levels of c-Myc 
might be responsible for the apoptosis. This experiment should be performed in a 
lymphoma cell line with a low endogenous level of YY1, since c-Myc levels are 
extremely critical to the downstream consequences on cell proliferation. It is 
known that low levels of c-Myc induce cell proliferation whereas high levels of c-
Myc induce apoptosis. As YY1 levels are high in the SuDHL6 cell line, any 
increased overexpression might lead to the c-Myc levels crossing the critical 
threshold required for the induction of apoptosis.  
My work has shown that the lymphomas in the Smurf2-deficient mice are 
germinal center derived. I have also shown that spleens from healthy, young, 
Smurf2-deficient mice proliferate better than WT. Characterization of the 
germinal centers in the Smurf2-deficient mice would provide insight into the 
process of lymphomagenesis in these mice. It would be interesting to test if the 
germinal center response was in someway enhanced in young Smurf2-deficient 
mice. It would also be interesting to extend this analysis further by immunizing 
the healthy Smurf2-deficient mice to elicit a germinal center response. If the 
germinal center response is enhanced in the immunized Smurf2-deficient mice, it 
would be interesting to observe if these immunized mice would develop 
185
lymphomas faster than the un-immunized Smurf2-deficient mice as this would 
greatly decrease the latency of lymphomagenesis in this mouse model.  
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